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Zusammenfassung 
Stromal-derived factor (SDF)-1/CXCL12 ist ein homöostatisches Chemokin, welches das 
Homing und die Aktivierung von Stammzellen fördert. Bisher ist unklar, warum Podozyten CXCL12 
konstitutiv freisetzen und warum die Inhibierung von CXCL12 zur Verminderung progressiver 
Glomerulosklerose beiträgt. Es ist anzunehmen, dass CXCL12 im Wesentlichen das Überleben und 
die Regenerierung von Podozyten reguliert. In-vitro konnte gezeigt werden, dass CXCL12 humane 
Podozyten vom toxischen Schaden schützt und eine in-vivo Blockade von CXCL12 zu einer 
verstärkten Proteinurie und einem Podozytenverlust in zwei unterschiedlichen Mausmodellen des 
toxischen Podozytenschadens führte. Stattdessen verhinderte die fortgesetzte Blockade von CXCL12 
signifikant den Verlust von Podozyten, die Proteinurie und Glomerulosklerose als Folge einer 
Adiamycin (ADR)-Nephropathie nach 14 Tagen- In der frühen Schadensphase führte CXCL12 
Blockade zu einem signifikanten Anstieg der Podozytenanzahl im Vergleich zur Vehiculum-
behandelten Gruppe auslöste, dies bedeutet, dass CXCL12 die Regeneration von Podozyten 
beeinträchtigt. Humane Nierenprogenitorzellen haben die Fähigkeit in reife Podozyten zu 
differenzieren. In Gegenwart von CXCL12 wurde das Wachstum der humanen 
Nierenprogenitorzellen und ihre Differenzierung in Podozyten unterdrückt, was durch CXCL12 
Inhibierung aufgehoben und somit das Outcome in Mäusen verbessert werden konnte. Dieser Effekt 
war abhängig von der Unterdrückung des Notch-Signalwegs in Podozytenprogenitorzellen, ausgelöst 
durch freigesetztes CXCL12 von nekrotischen Podozyten. Um dieses Phänomen genauer zu 
untersuchen, wurde eine ADR-Nephropathie in Mäusen induziert, welche eine in-vivo Verfolgung der 
Abstammung von Pax2+ Podozytenprogenitorzellen in der Bowman’s Kapsel ermöglichen. Die 
pharmakologische Inhibierung von CXCL12 erhöhte die Anzahl von Pax2+ Podozyten, was zur 
verminderten  Proteinurie und Glomerulosklerose in beiden Tiermodellen der ADR-Nephropathie 
führte. Schlussfolgernd kann man sagen, dass von Podozyten freigesetztes CXCL12 unterschiedliche 
biologische Funktionen bei einem Podozytenschaden hat. Zum Einen, dient CXCL12 als 
Überlebensfaktor für Podozyten, um Notch-vermittelte mitotische Katastrophe von Podozyten zu 
verhindern. Zum Anderen, kann CXCL12 den Arrest von Podozytenprogenitorzellen fördern, und 
dessen Blockade die Pax2+ Podozytenprogenitor-vermittelte Podozytenregeneration beschleunigen. 
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Summary 
Stromal-derived factor (SDF)-1/CXCL12 is a homeostatic chemokine facilitating the homing 
and activation of stem cells. It is unclear, why podocytes constitutively secrete CXCL12 and why 
CXCL12 blockade can attenuate progressive glomerulosclerosis. It can be assumed that CXCL12 plays 
a regulatory role on podocyte survival and podocyte regeneration. In-vitro CXCL12 protected human 
podocytes from toxic injury and in-vivo blocking intrinsic CXCL12 aggravated proteinuria and 
podocyte loss in two different mouse models of toxic podocyte injury. However, continued the 
blockade of intrinsic CXCL12 during the course of Adriamycin (ADR) nephropathy significantly 
attenuated podocyte loss, proteinuria, and glomerulosclerosis. Indeed, CXCL12 blockade significantly 
increased podocyte numbers not only as compared to vehicle-treated controls but also versus the 
earlier time point of injury, implying that intrinsic CXCL12 suppresses podocyte regeneration. To 
study this aspect, RPCs were used that have the capacity to differentiate into mature podocytes. 
CXCL12 suppressed progenitor growth and their induced differentiation into podocytes, which could 
be reversed by the same CXCL12 inhibitor that improved outcomes in mice. This effect depended on 
the suppression of Notch signaling in podocyte progenitors as being triggered by necrotic podocytes 
releases. To study this phenomenon in-vivo ADR nephropathy was induced in mice that allow lineage 
tracing of Pax2+ podocyte progenitor cells of the Bowman`s capsule. A delayed onset of 
pharmacological CXCL12 inhibition increased the number of Pax2 positive podocytes, an effect 
associated with less proteinuria and glomerulosclerosis in two different versions of the ADR 
nephropathy model. In conclusion, podocyte-derived CXCL12 has different biological functions 
during podocyte injury. First, CXCL12 serves as a podocyte survival factor, by preventing Notch-
mediated mitotic catastrophe of podocytes. Second, CXCL12 promotes podocyte progenitor 
quiescence, vice-versa, CXCL12 inhibition can accelerate Pax2+ podocyte progenitor-mediated 
podocyte regeneration.  
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1. Introduction 
1.1. Chronic Kidney Disease  
Chronic kidney disease (CKD) is defined as an irreversible and progressive decline of kidney 
function leading to kidney failure, known as end-stage renal disease (ESRD). It has been estimated 
that 14-15% of the adult population in the United States is affected by CKD and its prevalence has 
been estimated to increase by 50% over the next two decades (1, 2). CKD is defined by structural and  
functional abnormality of the kidney: albuminuria more then 3mg/mmol and  glomerular filtration 
rate less than 60ml/min/1.73m2 present for 3 months, with implications for health. CKD is mostly a 
consequence of podocyte loss-related glomerulosclerosis, e.g. in aging, diabetes, hypertension, and 
glomerulonephritis (3, 4).  
1.2.  Podocytes and the glomerular filtration barrier 
The glomerular filtration barrier is a highly specialized blood filtration interface that displays 
permeability to small- and midsized solutes in the plasma but restricts the flow of larger plasma 
proteins into the urinary space (Figure 1). The glomerular filtration barrier is a three-layered 
structure consisting of endothelial cells, glomerular basal membrane (GBM), and podocytes (5, 6). 
Podocytes, located outside the glomerular capillary loop, play a crucial role in the formation and 
maintenance of the glomerular filtration barrier. They have a complex cellular organization 
consisting of a large cell body leaning out of the urinary space and long cellular extensions (foot 
processes) that interdigitate with those of neighboring podocytes to cover the outer part of the GBM 
(5). Podocyte foot processes are anchored to the GBM through α3-β-integrins and β-dystroglycans 
(7). These characteristics, interdigitating patterns between foot processes of neighboring podocytes, 
are bridged by a 40nm wide zipper-like slit diaphragm (8). Podocyte foot processes and the 
interposed slit diaphragm cover the outer part of the GBM and play a major role in establishing the 
selective permeability of the glomerular filtration barrier (9). The glomerular filtration barrier is 
highly permeable to water and small solutes, but the small pore size (5-15nm) of the slit diaphragm 
limits the passage of larger proteins, for example, albumin (10). 
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Figure 1. The structure of the glomerulus and the cellular components. The GBM comprised of fenestrated 
glomerular endothelial cells (red cells), glomerular basement membrane and podocytes (dark green cells). The 
parietal epithelial cells (PECs) along the Bowman ’s capsule (yellow cells). Tubular cells in the urinary pole of 
the glomerulus (blue cells), PAS panoramic 1x, glomerulus magnification 40x) The image was adapted and used 
with the agreement of the copyright owner Duccio Lombardi and Laura Lasagni (see last page agreement), 
from Lombardi and Lasagni  et al(11),  
 
1.3. Focal Segmental Glomerulosclerosis 
Focal segmental glomerulosclerosis (FSGS) is not a single disease but rather a group of clinical-
pathologic syndromes sharing a common glomerular lesion and mediated by different types of 
insults within podocytes (12). FSGS is characterized by the presence of focal (in some isolated 
glomeruli) and segmental (in some part of a single glomerulus) lesions with obliteration of 
glomerular capillaries, adhesion with the glomerular tuft and BC and podocyte hypertrophy (13). 
More than 80% of FSGS cases are classified as idiopathic if the cause is unknown. A genetic mutation 
affecting podocytes proteins have been identified as the primary cause of sporadic types of FSGS, 
often these mutations correlate with the nephrotic syndrome and they have a familiar genetic 
outcome (14). in particularly the mutations have been found in the podocyte protein of the slit 
diaphragm as Nephrin, Podocin and CD2-associated protein (CD2AP) (15-17) or inside the podocyte 
nucleus as Wilms-tumor protein 1 (WT-1) (18, 19). Sclerosis of the glomerulus occurs as a response 
to injury. The functional kidney is then replaced by scarring tissue, leading to progressive and 
irreversible loss of function. The glomerular structure consists of an endo-capillary compartment 
containing mesangial cells and capillaries, and an extra-capillary compartment containing podocytes 
and the parietal epithelial cells (PECs) lying on the Bowman´s capsule (20). The “spine cord” of this 
structure is maintained by podocytes, are terminally differentiated epithelial cells that are 
specialized to their architecture, and are responsible for the maintenance of the GBM and the GFB 
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as shown in Figure 1. A recent study was able to show that all forms of glomerulosclerosis start with 
either a lesion or a dysfunction of podocytes (21). This is true for many kidney diseases, with 
particularly important in that disease that give a late onset like diabetic nephropathy or FSGS feature 
of many kidney diseases with late onset like diabetic disease (22), FSGS (23, 24). High cytoskeleton 
complexity and physiological-complex structure of podocyte is the reason for the limited capacity for 
cell cycle re-entry and proliferation for replacing podocyte loss (25). When podocytes are lost during 
glomerular injury how can the glomerulus maintain the structure and part of its functionality? Till 
today, this question is not completely undertaken and many hypotheses have been formulated: 
podocyte hypertrophy that rescued and increased glomerular workload (26) and  podocyte 
replacement by activated renal stem cell progenitors (RPCs) recruitment (27, 28). However, 
podocyte hypertrophy or RPCs replacement occurs slowly and can lead to d loss of GBM integrity 
(29). Loss of podocytes will end in a formation of “uncover” GBM and the loss of distance between 
the capillary tuft and the BC allow PECs of the Bowman´s capsule to start to form the multi-layer 
formation, that cover the tuft and create a fibrotic scar as known as crescent formation (30, 31). 
Crescent formation may stop the entire afflicted glomerulus, this process compromises the other 
lobules leading to a segmental or later global sclerosis (32). There are several studies with transgenic 
animal models that showed a correlation between the severity and progression of sclerotic lesions 
and the amount of podocyte loss (29, 33). When mild podocyte loss is occurring (20% or less) the 
effects on the glomerular architecture can be just transient with low proteinuria and no real change 
in renal function (34). If the loss is more than 40%, the remaining podocytes cannot compensate, 
which is associated with the crescent formation, FSGS and mild proteinuria in the absence of 
changes in renal function. However, scar formation can be detected and seen as a result of an 
excessive repair mechanism (35). Over 40% of podocyte loss, a considerable proportion of glomeruli 
with adhesions and high proteinuria can be observed.  
1.4. Adriamycin-induced focal segmental glomerulosclerosis 
ADR nephropathy is a highly reproducible and robust model of proteinuric renal disease, 
resulting from selective podocyte injury (36). In rodents, like in the Balb/c mouse strain, a single 
injection of ADR also knows as doxorubicin, induces kidney damage that mimics human FSGS(37). 
ADR is an anthracycline antibiotic with pleiotropic cytotoxic effects used for the treatment of a wide 
spectrum of human cancers. It is a DNA intercalating agent, which inhibits the enzyme 
topoisomerase II and thereby generates free radicals, which induce DNA damage and subsequent 
cell death (38). Balb/cmice have shown a high susceptibility to ADR injection compared to C57BL/c 
mice that are highly resistant and multiple ADR injections were required to develop a 
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glomerulosclerosis. 1-2 weeks after ADR administration, altered renal function and induced thinning 
of the glomerular endothelium together with altered podocytes structure, in particular inside the SD. 
Loss of podocyte from the GBM is the normal epilog (39). Importantly, it was proved on severe 
combined immunodeficiency (SCID) mice that the structural and functional injury induced by ADR 
was not involving immune cell activation (40).  
1.5. Podocyte regeneration from glomerular progenitors 
The kidneys have been classically considered as organs with low capacity for regeneration. 
Mesangial and endothelial cells have been reported to have the capacity to proliferate and replace 
the loss of neighboring cells upon insult, but this does not apply to podocytes(41). Podocytes are 
terminally differentiated cells and are unable to proliferate (42). The loss of these specialized cells is 
a common cause of FSGS and progressive CKD (35).  
 
Figure 2. Representation of the glomerulus structure and cells components. The GBM comprised of 
fenestrated glomerular endothelial cells (red cells), glomerular basement membrane and podocytes (dark 
green cells). The parietal epithelial cells (PECs) along are present along the Bowman´s basement membrane 
during RPCs differentiation toward podocyte lineage after RPCs activation from the renal stem cell niche. (The 
image was adapted and used with the agreement of the copyright owners Duccio Lombardi and Laura Lasagni 
(see last page agreement), from Lombardi and Lasagni  et a(11)l).  
 
Recently, it has been proved that adult human glomeruli contain resident stem cell 
populations in a stem cell niche localized at the urinary pole of the Bowman´s capsule. This 
population is identified by the presence of cluster of differentiation 24 (CD24) and prominin-1 
(CD133) (43-45) and has self-renewal properties and the capacity to differentiate into podocytes or 
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into tubular cells, in-vitro and in-vivo (35, 46). This double positive population demonstrated their 
capacity to proliferate and differentiate along the Bowman´s capsule, move to the vascular stalk and 
generating neo-podocytes. However, in glomerular disorders, characterized by acute or severe 
podocyte loss, the regenerative capacity of epithelial glomerular stem cells is inadequate because of 
an imbalance between the proliferative response and the degree of damage (47, 48). In addition, 
crescentic glomerulonephritis or collapsing glomerulopathy shows excessive proliferative response 
by RPCs (31, 49-51). This reflects the inability to restore lost podocytes, contributing to the crescent 
formation and glomerulosclerosis (31, 52, 53). Glomerular renal progenitors display different 
regenerative potentials throughout distinct disease stages and are modulated by the surrounding 
environment (54, 55).  In a recent article by Peired et al., one of the environmental factors that 
deregulated the RPC-induced regeneration and the amount of albumin in the urinary proteinuria 
was described (56). This study demonstrated that albumin impaired the RPC capacity to differentiate 
into podocytes. Albumin has the dose-dependent capacity and the affinity to sequestering the 
retinoic acid (RA). After GBM damage, the retinol passed in the Bowman’s space was transformed in 
RA by the podocyte retinaldehyde dehydrogenases (Aldh1) enzyme. RPCs differentiation was a direct 
consequence of RA accumulation in the Bowman´s space. Retinoic acid-induced PECs differentiation 
toward podocytes lineage by the retinoic acid response element (RARE) is shown in Figure 3 (56).  
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Figure 3. Renal progenitor cell differentiation toward podocyte lineage in mild proteinuria status. In a mild 
glomerular proteinuria disease, the podocytes can derivate (green and red/green cells) RA from the blood 
retinol and activates RPCs (red cells) can fully differentiate to podocyte. (right part). When proteinuria levels 
are too high in the BS, the RA is sequester by the albumin and the RPCs proliferation is not stopped by the 
differentiation toward podocyte lineage. RPCs uncontrolled proliferation can generate crescent formations 
(red cells) and consequently glomerular sclerosis and degeneration is established. (The image was adapted and 
used with the agreement of the copyright owners Duccio Lombardi e Laura Lasagni, from Lombardi and 
Lasagni et al,(11)). 
Albumin is a high-affinity carrier of RA in the blood stream, which explains why a reduced 
quantity of albumin in the glomerular space was able to bind all RA, reducing drastically the major 
RPC differentiation factor and impairment of glomerular regeneration (56). As a result of this 
prolonged albumin lack, the activated and proliferating RPCs were not able to finalize the 
differentiation program toward podocytes leading to an accumulation of PECs in the BC and BS, that 
can degenerate to crescent formations, and finally to FSGS disease (30, 35, 56), as shown in Figure 4. 
However, further studies needs to be done to be able to fully understand the complex plethora of 
stimuli, which induce RPC regeneration.  
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Figure 4. RPC over proliferation can generate crescents formations in high proteinuria status. When 
proteinuria levels are too high in the BS, the RA (orange triangle) is sequester by the albumin (brown half dot) 
and the RPCs proliferation (yellow cells) is not stopped by the differentiation toward podocyte lineage. RPCs 
uncontrolled proliferation can generate crescent formations (orange areas) and consequently glomerular 
sclerosis and degeneration is established. (The image was adapted and used with the agreement of the 
copyright owners Duccio Lombardi e Laura Lasagni, from Lombardi and Lasagni et al,(11)) 
 
1.6. Notch pathway 
The Notch (neurogenic locus notch homolog protein) pathway was discovered in Drosophila 
melanogaster in 1917 by T.H. Morgan (57). At the beginning of the ‘80s, the Notch gene was found 
to encode a 300kDa single-pass transmembrane receptor (58). It was established that Notch was 
involved in cellular signaling and contains multiple conserved protein domains. In mammals, four 
Notch receptors (Notch 1-2-3-4) and five trans-membrane ligands Jagged-1-2 (Jag-1-2), Delta-like1-3-
4 (Dll-1-2-3-4) have been identified (59). The Notch signaling cascade appears simple with few or no 
second messengers involved as shown in Figure 5. 
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Figure 5. Notch pathway, ligands, receptors, and downstream genes. After the cuts from the proteases ADAM 
and gamma-secretase, the NICD entered in the nucleus and makes the complex with recombination signal 
sequence-binding protein-jk (RBP-jk) and the activator to starts Hey and Hes, Notch downstream genes 
activation. 
However, the role of Notch signaling and the activation of downstream genes in many 
tissues remain complex and in many cases, unpredictable (59). The Notch signaling cascade is 
activated upon cell-to-cell contact as a result of interactions between Notch receptors and their 
ligands (60). At the molecular level Notch activation promotes two cleavage events on the Notch 
receptor (Figure 5). The first cleavage is catalyzed by the A-Disintegrin-And-Metalloproteinase 
(ADAM)-family-metalloproteases, whereas the second cleavage is mediated by gamma-secretase, a 
complex enzyme that contains presenilin and nicastrin (60). The second cleavage releases the Notch 
intracellular domain (NICD), which then translocates to the nucleus and acts as a transcriptional 
factor. NICD is a co-factor DNA binding protein RBP-jk and can activate the transcription of genes 
containing RBP-Jk binding sites. NICD binding to RBP-J is crucial for the switch from a repressed to an 
activated state. Notch receptors have diverse outcomes, only a fairly limited set of Notch target 
genes have been identified in various cellular and developmental contexts (60, 61). Therefore, in 
mammals, the best-described Notch target genes are the transcription factors Hey-1 and Hes-1-5-7 
(62, 63). Hes and Hey proteins are helix-loop-helix transcription factors that function as 
transcriptional repressors. Hes-1 deficient mice are not viable and display multiple developmental 
defects (61). Signaling mediated by Notch receptors and ligands is involved in regulation of many 
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biological functions including cell proliferation and differentiation (64), and  homeostasis of adult 
self-renewing organs (65).  
Notch signaling can also drive a terminal differentiation program by inducing cell cycle arrest 
like it is observed in keratinocytes in the skin. Notch regulates binary cell fate decisions and stem 
cells maintenance. A second general role of Notch is to promote the development of a given cell 
type or body region, often by inducing the expression of positively acting regulatory molecules. For 
example, in mammals, Notch signaling induces a terminal differentiation program in human skin (65, 
66). In the kidney, it is known from the literature, that the Notch pathway is very important during 
the nephrogenesis of fetal kidney development (67).  However, a very delicate equilibrium is set 
inside the glomerulus between Notch activation and its suppression. Lasagni, et al. (64) have 
demonstrated a double role of the Notch pathway during the endogenous podocyte-RPCs-driven 
regeneration after ADR nephropathy. In the context of glomerular ADR disease using SCID mice, the 
Notch pathway activation was negative for podocytes. Podocytes can start DNA synthesis for the cell 
cycle, but they cannot complete the cytokinesis. The principal reason was the very end-
differentiated podocyte structure. Indeed, when podocytes re-enter the cell cycle, they would 
literally “destroy” the specific and characteristic cytoskeleton structure, in particular, the actin 
system (68, 69). In a disease condition, where many podocytes are lost or in a critical status, Notch 
activation of the Notch 1 receptor is the primarily induced signal (27) and  can finally trigger GBM 
detachment or cell death. A recent study reported that if podocytes were forced to entry in mitosis, 
mitotic catastrophe (CM) can be established (42). DNA synthesis and chromosome segregation 
cannot complete cytokinesis due to poor expression of Aurora Kinase B, which is essential for this 
process (64, 70, 71) (Figure 6). Abnormal mitotic podocytes expressing histone H3 were observed in 
ADR-induced FSGS models and podocyte death through catastrophic mitosis was prevented by 
treatment with Notch inhibitors. This Notch activation mediated the down-regulation of cell cycle 
inhibitors that force podocytes to progress toward mitosis (64).  
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Figure 6. Destinies of a re-entry cell cycle podocyte after injury. Podocytes complete the DNA synthesis but 
cannot proceed through the M phase (A) owing to the activation of mitotic catastrophe. (B) increase their size 
thus becoming hypertrophic. When division cannot be complete and cytokinesis fails, cells with gross nuclear 
alterations are generated which quickly undergo “mitotic death” program; D) cells can exit mitosis containing a 
variable number of nuclei or micronuclei; these cells are viable because lethal pathway is not executed until 
cells reach interphase of the next cell cycle, but are unstable and detach from the GBM (C); in this case, cell 
death can occur in a delayed fashion even after years; E) when the aberrant division is productive aneuploidy 
cells form; most of these are unviable, owing to chromosomal rearrangements that result in progressive 
detachment to eliminate genomically unstable cells.  
RPCs are highly activated by the Notch pathway, in particularly the Notch-3 receptor that 
leads RPCs to proliferate during AN, even after 21 days after the model induction, where Notch-3 
was still strongly expressed in RPCs compared to the Notch-1 receptor (64). This positive PRC 
activation via the Notch pathway in an in-vivo model was further proven when a Notch inhibitor was 
injected in the FGSG model. The urine proteinuria was reduced at the beginning of the model on day 
7 when Notch blockade dues to reduced podocyte’ CM induction and less podocyte loss ratio. 
Nevertheless, the final outcome of the disease during the regenerative phase was compromised by 
the Notch inhibition effects on RPC proliferation and differentiation toward podocytes. The final 
number of podocytes in the glomeruli after inhibition was assessed and reduced in the treated group 
compared to the control (64). Also, Lasagni, et al. demonstrated the differential role of Notch 
signaling in several in-vitro experiments with RPCs and Notch inhibitors (64).  
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1.7. Stromal-derived factor 1 (SDF-1)/CXCL12 
CXCL12, previously named stromal-derived factor 1 (SDF-1), was first described as a growth 
factor for pre-B cells but turned out to be also expressed in numerous hematopoietic and non-
hematopoietic tissues (72) (Table.1). Nowadays, CXCL12 is known to be an essential regulator of 
progenitor cell homing and recruitment (73, 74), which includes bone marrow progenitors of the 
hematopoietic system as well as committed progenitors in peripheral tissues (75, 76). In addition, 
like pro-inflammatory chemokines, CXCL12 is induced following tissue injury and mediates the 
recruitment of progenitor and effector cells, which further contribute to tissue injury as well as 
wound healing (76, 77). CXCL12 mediates its biological effects via the receptors CXCR-4 and CXCR-7, 
which can form hetero- or homodimers and exert a variety of different biological effects. The 
CXCL12/CXCR4/7 axis can be modulated by pharmacological intervention in various diseases (78-80) 
including abdominal aortic aneurysm and diabetic nephropathy (81-83). In breast and colon cancer 
as well as renal cell carcinoma (RCC), blockade of the CXCL12/CXCR-4 interaction has been shown to 
reduce the ability to make metastasis due to CXCL12-dependent invasion and migration mechanisms 
(84-87).  
Table 1. CXCL12/CXCR-4/CXCR-7 positive cells 
List of abbreviations: Renal Progenitors cell; RPCs, Tubular endothelial cell; TECs, Hematopoietic 
stem cells; HPSC, Bone marrow mesenchymal stem cell; BMSCs, Endothelial Progenitor cells; EPCs. 
Cell type CXCL12 CXCR-4 CXCR-7 
Podocytes (82, 83) + + + 
RPCs (88) - + + 
TECs (89) + + + 
HPSCs (90, 91) - + + 
BMSCs (92, 93) + + - 
Neutrophils (94, 95) - + + 
RCC (96, 97) + + + 
EPCs (98, 99) - + + 
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1.8. CXCL12 in kidney development 
Embryonic development requires directed progenitor cell migration (100). For example, the fetal 
bone marrow expresses high levels of CXCL12, which promotes the migration and homing of myeloid 
cells from the fetal liver (72). However, CXCR-7 seems redundant in mice because CXCR-7-deficient 
mice do not show abnormal hematopoietic tissue or hematopoiesis (101, 102). CXCR-7 is a critical 
regulator of CXCR-4-mediated migration of primordial germ cells and one of the main fine regulators 
of the signaling between podocytes and glomerular capillaries (103). Self-generated CXCL12 
gradients by polarized CXCR-7 internalization support a self-directed stem cell migration in the 
capillary tuft (103, 104). The developing kidney expresses CXCL12 and CXCR-4 in the comma and S-
shaped body, the mesangium, and the collecting ducts (105, 106). Inside the glomerulus, CXCL12-
expressing podocytes are in close touch to CXCR-4+ endothelial cells located in the vascular cleft in 
the S-phase of forming glomerulus (106). Targeted deletion of CXCL12 or CXCR-4 resulted in 
defective blood vessel formation with a highly disorganized vasculature in the glomerular tufts (106). 
Deleting CXCR-4 selectively in endothelial cells gave a similar phenotype (106). Interestingly, no 
defects were found in mice with Cxcr-4-deficient podocytes suggesting that podocyte-derived 
CXCL12 is a paracrine signal for endothelial cells (106), conceptually similar to the glomerular 
vascular endothelial growth factor (VEGF) system (107). Doná et al. clarified several aspects of such 
CXCL12 gradients during kidney development, they showed an important impact for the CXCL12 
atypical receptor CXCR-7 during the generation of the migration gradient (104). 
1.9. CXCL12 in stem cell homing and homeostasis outside and inside the kidney 
Hematopoietic stem and progenitor cells (HSCs) and their niches in the bone marrow (BM) are one 
of the most studied stem cell systems. CXCL12 is the predominant signal that maintains CXCR-4+ve 
HSCs quiescent inside the bone marrow stem cells niche (108, 109). In the perivascular niche, 
CXCL12-abundant reticular cells (CAR) as shown in Figure 7, constitutively express CXCL12 to 
facilitate the homing of CXCR-4+ blood cell progenitors and endothelial progenitor cells (EPCs) (108). 
In contrast, osteoblasts along the inner bone surface home more immature and quiescent HSCs to 
the endosteum niche (108). CXCL12 also induces the production of matrix metalloprotease 9 (MMP-
9) and the shedding of the CD117 ligand to mobilize quiescent HSCs from the vascular niche to 
expand before mature granulocytes and monocytes egress into the blood (102). Consistent with this, 
genetic variants that increase CXCR-4 signaling can cause a hypercellular bone marrow and 
peripheral blood neutropenia (110). In addition, CXCL12 also regulates the senescent return of 
neutrophils to the bone marrow for clearance (94). In this process, neutrophils increase CXCR-4 
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expression on their surface, becoming susceptible to CXCL12 in the bone marrow, which facilitates 
their re-entry via phagocytosis by bone marrow macrophages (94). 
 
Figure 7. Homeostatic chemokines in hematopoietic stem cell homing or trafficking. Bone marrow. HSCs 
reside in two different niches within the bone marrow. The hypoxic endosteal niche is generated by bone-
lining cells producing CXCL12, which keeps the cells largely in an immobile and quiescent state. The 
perivascular niche is formed by perivascular CXCL12 abundant reticular (CAR) cells, which support homing 
within the bone marrow, cell division, and evasion of blood cells into the blood stream. Neutrophils are shown 
at the  bottom of the figure, and  immature lymphocytes in the upper part, respectively. Senescent neutrophils 
also return to the bone marrow for phagocytic clearance upon upregulation of CXCR-4.  
Further support comes from CXCL12 or CXCR-4-deficient mice, which show a severe defect of 
myelopoiesis (111). It is of note that the central role of CXCL12/CXCR-4 in regulating HSC homing has 
been exploited for clinical purposes: a single injection of a CXCR-4 antagonist is sufficient to mobilize 
HSCs and other progenitor cells from the bone marrow into the peripheral blood (112); therefore 
representing a possible therapeutic approach used beyond mobilization of HPSCs (113). Inside the 
kidney, podocytes produce the vascular endothelial growth factor (VEGF) to maintain normal 
glomerular capillaries and contribute to endothelial regeneration after glomerular injury (114). 
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CXCL12 expressed by mature podocytes acts on endothelial cells but also on other glomerular cells, 
such as RPCs from BC identified as CD24+ and CD133+ cells, that showed increased CXCL12/CXCR-7-
mediated survival in-vitro after H2O2 stimulation (88). The CXCL12 ability to maintain tissue in 
homeostasis by regulating podocytes, capillary endothelial cells and RPCs, could be crucial to 
modulate the outcome of kidney disease. Moreover, the consequent aspect necessary to be defined 
is the pathogenic role of CXCL12 during kidney disease.  
1.10. Pathogenic roles of CXCL12 during kidney disease 
Glomerulonephritis. In human biopsies of IgA nephropathy and extra-capillary 
glomerulonephritis, high levels of CXCR-4 expression was revealed in hyperplastic lesions by 
immune-fluorescent staining, associated with a positivity for CD24+ progenitor cells (115). On the 
contrary, in patients with membrane nephropathy or diabetes, the positivity of CXCR-4 expression 
was faint (115). Moreover, in a mouse model of diabetic nephropathy, the podocytes were the 
major producer of CXCL12 as demonstrated by CXCL12 protein quantification and tissue staining 
(83). CXCL12 is produced by podocytes in a state of health similar to that during glomerular disease 
(83, 116). Interestingly, CXCL12 expression can be further increased by podocytes during 
glomerulonephritis. This deregulation of CXCL12 production seems to be related to the development 
of nephritis (116). The reversal of nephritis in New Zealand Black/New Zealand White (NZB/W) mice 
treated with an anti-CXCL12 monoclonal antibody (mAb) had effects on both levels, systemically and 
locally (116). The CXCL12/CXCR-4 axis is involved in such excessive epithelial hyperplasia, which is 
presented as crescentic glomerulonephritis (35, 117). Crescentic glomerulonephritis and collapsing 
glomerulopathy are both characterized by podocyte loss and inappropriate hyperplasia of mal-
differentiated epithelial cells (118). It has been demonstrated that in the tip lesion as well as in FSGS, 
both characterized by some hyperplasia, glomerular RPCs are the main constituents of the 
proliferative lesion (52). RPCs can also consequently form tip lesion as described during FSGS and 
diabetic nephropathy (52). In diabetic nephropathy CXCL12 is located within the cytoplasm of the 
podocytes during the advanced phase of the disease (83). In a study by Rizzo, et al. CXCR-4 was 
found to be expressed by activated PECs and CXCL12 was produced by podocytes in Munich Wistar 
Frömter (MWF) rats, which develop progressive glomerular injury (115). Using a diabetic C57BLKS 
db/db mouse model, Sayyed, et al. showed that blockade of CXCL12 ameliorates glomerular disease 
markers and increases the number of podocytes to maintain the peritubular vasculature without 
affecting glucose levels or glomerular macrophages infiltration (83). Furthermore, Darisipudi, et al. 
revealed that CXCL12 blockade increases the differentiation capacity of RPCs towards podocytes, 
and reduces the loss of nephron levels in the total kidney of diabetic mice (82). Along the same line, 
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CXCR-4 re-expression in adult podocytes could drive autocrine actions of nephrosclerosis, a common 
manifestation of chronic microvascular disease (119). This may also include mobilization and 
detachment of podocytes from the glomerular basement membrane, a process known to lead to 
glomerulosclerosis and chronic kidney disease. Together, the data emphasize the fact that blocking 
CXCL12 and its receptors in a time-dependent way could be an important tool to modulate and 
ameliorate glomerular pathologies (109).  
Tubular injury. Acute kidney injury (AKI) is characterized by a rapid decrease in excretory renal 
function and sometimes also with a decrease in urinary output within hours to days, either due to a 
decline in renal blood perfusion, intrarenal injuries such as acute tubular necrosis (ATN) or urinary 
outflow obstruction (120). During ATN, increased hypoxia level, can induce tubular cells CXCL12 
secretion. The distal convolute tubules and collecting ducts also showed high expression levels of 
CXCL12  in the cytoplasm and CXCR-4 on the plasma membrane (121). Proximal tubules were also 
positive for CXCL12, whereas the renal interstitium was negative (121). CXCL12 can trigger 
neutrophil infiltration during an ischemic insult leading the tubular inflammation (121). The renal 
ischemia-reperfusion (IR) injury is a common cause for AKI, associated with high morbidity and 
mortality, that can affect native and transplanted kidneys (122). As for the glomerular compartment, 
the CXCL12 expression is increased during kidney IR. In particular, bilateral IR induces a strong 
expression of CXCL12 in tubular epithelial cells (TECs) of ischemic kidneys after one day compared to 
contro-lateral kidneys (123). However, CXCL12 levels return to baseline after 10 days following 
surgery. Stokman, et al. have investigated this increased production of CXCL12 to answer the 
question whether high levels of CXCL12 are a pre-requisite for starting the regeneration phase of the 
tubular compartment after IR via bone marrow stem cells (HSCs) mobilization and differentiation 
towards TECs (123). Surprisingly, blocking CXCL12 with an antisense oligonucleotides (ASON) did not 
alter the influx of HSCs and had no effect on tubular regeneration compare to treatment with 
nonsense oligonucleotides (NSON) (123). Instead, ASON-CXCL12 showed that CXCL12 was required 
to improve TECs survival during IR compared to CXCL12-nonsense oligonucleotides (NSON) blockade 
(123). Together, CXCL12 displays opposite roles during IR injury: (1) CXCL12 is an important 
chemoattractant for neutrophils during tubular injury as shown in Figure 8, and (2) it is a crucial 
factor in avoiding cell death of TECs as well as helping the recovery of TECs after IR. (3) CXCL12 also 
triggers the infiltration of immune cells towards the injured tubular compartment to promote 
healing by serving as a survival factor for tubular cells; however this concept remains to be evaluated 
in more details.  
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Figure 8. Figure 6. CXCL12 in homeostasis and AKI. In the upper panel, CXCL12 effects on the neutrophils 
clearance are shown. Also, CXCL12 has a role in many tissue progenitor replenishment. In the bone marrow, as 
well as in other organs CXCL12 effects are strongly regulated by the hypoxia. In the lower panel is shown how, 
during acute injury the increased level of hypoxia can lead to several tissues to secrete higher levels of CXCL12 
with subsequential inflammatory cell recruitment in the diseased compartment.  
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1.11. CXCL12 and kidney regeneration 
Commonly, in adult tissues, stem cells are the principal players involved in self-renewal, 
proliferation, and multipotent differentiation capability in-vivo (124). The mammalian kidney shares 
with other organs the ability to partially resolve the damaged structures after injury. Tubular 
integrity, for instance, can be restored after acute damage, and glomerular disorders can sometimes 
undergo regression by re-epithelialization (53, 125). Research on the functional role of RPCs has 
been of great interest in the last years due to a potential importance of RPCs for de-novo 
regeneration of podocyte loss following glomerular injury (28). Mazzinghi, et al. identified the 
mechanisms that are involved in the therapeutic homing of human renal progenitors into the injured 
kidney (88). Using a radioactive assay, they were able to show the expression of CXCR-4 and CXCR-7 
on the surface of human renal progenitors (88). A dual blockade of CXCR-4 and CXCR-7 to assess the 
regenerative capacity of injected human RPCs during kidney damage was induced by glycerol 
injection in SCID (88). They further demonstrated that the interaction between CXCL12 and both 
receptors are important for the homing and regeneration of the kidney. Of note, CXCR-4 is required 
for RPC chemotaxis and migration, while CXCR-7 is necessary for RPCs transendothelial migration 
and subsequently the adhesion to the extracellular compartment (88). Another study showed that 
blocking CXCL12 for 8 weeks in a male diabetic C57BLKS db/db uninephrectomized mouse model 
resulted in increased numbers of infiltrating cells in each glomerulus that were positive for the 
podocyte marker Wilms-tumor protein1 (WT-1) compared to control mice (82). Also, total kidney 
mRNA-RT-PCR evaluation of the podocyte marker nephrin showed an increased expression following 
blockade of CXCL12 (82). Furthermore, Darisipudi, et al. (82) showed that blocking CXCL12 during 
RPC differentiation toward podocyte lineage under VRAD medium stimulation in vitro that the mRNA 
level of nephrin increased in podocytes (82). CXCL12 is also known to play a key role during EPCs 
mobilization. To investigate this, Bo, et al. designed a tubular ischemia precondition (IPC) before 
inducing a severe IR damage (126). They were able to raise CXCL12 and VEGF levels in the kidney and 
the subsequent mobilization of EPCs towards the tubular compartment resulting in a better AKI 
outcome (126). These data suggest that EPCs and CXCL12 have a renal protective role in the late 
phase of IR injury by regulating endothelial cell dysfunction (126).  
1.12. Spiegelmer, a next generation aptamer 
Klussman, et al. (86, 127-129) and  Darisipudi, et al. (82), showed the CXCL12 was a good 
target inside and outside the glomerular diseases. Within this thesis, the CXCL12 antagonist from 
NOXXON Pharma called NOX-A12 was used (113), a chiral molecule specific for CXCL12 that was 
obtained via SELEX technology (Figure 9). This Spiegelmer (NOX-A12 antagonist) has been identified 
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to be highly selective, non-immunogenic, save and body well-tolerated and highly stable in plasma. 
The preparation of the mirror-image target that was required for the screening process is important 
and sometimes challenging step, particularly when targets are chemically or biologically more 
complex. Whereas, smaller peptide targets that are more easily accessible for the Spiegelmer 
discovery and development. Until now, several different studies and clinical trials have been 
successfully undertaken using the NOX-A12 antagonist animal models e.g.: CXCL12 Inhibition during 
bone marrow cancer therapy (128-130) as well as preclinical and clinical studies e.g. Spiegelmer 
NOX-A12, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization  
(131). Therefore NOX-A12 was used to inhibit CXCL12 in all experiments within this thesis. 
 
 
 
Figure 9. The representative process to obtain an RNA-spiegelmer against the chemokine CXCL12.  Mirror 
image of CXCL12 is synthesized. RNA aptamers binding to the mirror-image are selected by in-vitro synthetic 
ribonucleotide library in the natural D-configuration. The D-configuration is required because stereoselective 
enzymes are used for amplification, cloning, and sequencing of bound sequences. The finals identified 
sequences were synthesized using an (L)-ribonucleotides like an NOX-A12 spiegelmer after poly-etilen glycol 
molecular stabilization.  
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2. Hypotheses 
In search of a potential cure for progressive glomerulosclerosis we previously found that 
blocking the chemokine CXCL12 protected mice with type 2 diabetes from albuminuria, podocyte 
loss, progressive glomerulosclerosis and CKD (82, 83). The pathophysiology behind this 
renoprotective effect is unclear. During glomerular disease, podocytes are the major producer of 
CXCL12. The role of CXCL12 in the glomerulus was studied intensively by Romagnani, et al. (88) in 
the field of RPC recruitment and survival during glomerular disease, however, the mechanisms are 
still not fully understood, especially the release of CXCL12 by podocytes under healthy and disease 
conditions.  
Therefore, the following hypotheses were raised: 
 CXCL12 produced by podocytes may serve as an autocrine survival factor for podocytes 
during glomerular injury. 
 CXCL12 drives the proliferation and differentiation of RPCs toward the podocytes lineage 
during glomerular disease by inhibiting Notch  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods                                                                                                            
22 
 
3. Materials and Methods 
3.1 Instruments and Chemicals 
3.1.1 Chemicals and Reagents 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
RT-PCR primers Metabion, Munich, Germany 
Cell culture:  
DMEM-F12 medium Sigma, Munich, Germany 
RPMI-1640 medium GIBCO/Invitrogen, Paisley, Scotland, UK 
FBS 
FBS Hyclone 
EBM 
EGM-MV 
Biochrom KG, Berlin, Germany 
ThermoScientific, UT, USA 
Lonza, Cologne, Germany 
Lonza, Cologne, Germany 
CXCL12 immunotools 
Trypsine/EDTA (1×) PAA Laboratories GmbH, Cölbe, Germany 
Penicillin/Streptomycin (100×) PAA Laboratories GmbH, Cölbe, Germany 
All-trans retinoic acid 
Vitamin 3D 
Antibodies: 
Sigma, Munich, Germany 
Sigma, Munich, Germany 
Nephrin 
WT-1 
Santa Cruz Biotechnologies, Santa Cruz, CA 
Santa Cruz Biotechnologies, Santa Cruz, CA 
DAPI Invitrogen, Darmstadt, Germany 
Alexa Fluor 488 anti-rat IgG1 
Alexa Fluor 546 anti-rabbit IgG1 
Alexa flour 488 anti-goat  
Alexa Fluor 488 anti-mouse IgG1 
Alexa Fluor 546 anti-mouse IgG1 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
Invitrogen, Darmstadt, Germany 
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HRP linked Anti-Rabbit secondary  Cell signaling, Danvers, MA 
HRP linked Anti-Mouse secondary  Cell signaling, Danvers, MA 
HRP linked Anti-Goat secondary  Dianova, Hamburg, Germany 
β-Actin Cell signaling, Danvers, MA 
Elisa Kits:  
Mouse Albumin Bethyl Laboratories, TX, USA 
Creatinine FS 
Urea FS 
DiaSys Diagnostic System, Holzheim, Germany 
DiaSys Diagnostic System, Holzheim, Germany 
Chemicals:  
Acetone Merck, Darmstadt, Germany 
AEC Substrate Packing Biogenex, San Ramon, USA 
Bovines Serum Albumin Roche Diagnostics, Mannheim, Germany 
Skim milk powder Merck, Darmstadt, Germany 
DEPC Fluka, Buchs, Switzerland 
DMSO Merck, Darmstadt, Germany 
EDTA Calbiochem, SanDiego, USA 
30% Acrylamide Carl Roth GmbH, Karlsruhe, Germany 
TEMED Santa Cruz Biotechnology, Santa Cruz, CA 
Eosin Sigma, Deisenhofen, Germany 
Ethanol Merck, Darmstadt, Germany 
Formalin Merck, Darmstadt, Germany 
Hydroxyethyl cellulose Sigma-Aldrich, Steinheim, Germany 
HCl (5N) Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Calcium dihydrogenphosphate Merck, Darmstadt, Germany 
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Calcium hydroxide Merck, Darmstadt, Germany 
Beta mercaptoethanol Roth, Karlsruhe, Germany 
Sodium acetate Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dihydrogenphosphate Merck, Darmstadt, Germany 
Penicillin Sigma, Deisenhofen, Germany 
Roti-Aqua-Phenol Carl Roth GmbH, Karlsruhe, Germany 
Streptomycin Sigma, Deisenhofen, Germany 
Tissue Freezing Medium Leica, Nussloch, Germany 
Trypan Blue Sigma, Deisenhofen, Germany 
Xylol Merck, Darmstadt, Germany 
Miscellaneous:  
LDH Roche diagnostic, Switzerland  
Cell Titer 96 Proliferation Assay  Promega, Mannheim, Germany 
Pre-separation Filters Miltenyl Biotec, Bergish Gladbach, Germany 
Super Frost® Plus microscope slides  Menzel-Gläser, Braunschweig, Germany 
Needles BD Drogheda, Ireland 
Pipette’s tip 1-1000μL Eppendorf, Hamburg, Germany 
Syringes Becton Dickinson GmbH, Heidelberg, Germany 
Plastic histocasettes NeoLab, Heidelberg, Germany 
Tissue culture dishes Ø 100x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 150x20mm TPP, Trasadingen, Switzerland 
Tissue culture dishes Ø 35x10mm Becton Dickinson, Franklin Lakes, NJ, USA 
Tissue culture flasks 150 cm2 TPP, Trasadingen, Switzerland 
Tubes 15 and 50 mL TPP, Trasadingen, Switzerland 
Materials and Methods                                                                                                            
25 
 
Tubes 1.5 and 2 mL TPP, Trasadingen, Switzerland  
Balance:  
Analytic Balance, BP 110 S Sartorius, Göttingen, Germany 
Mettler PJ 3000 Mettler-Toledo, Greifensee, Switzerland 
Cell Incubators:  
Type B5060 EC-CO2 Heraeus Sepatech, München, Germany 
Centrifuges:  
Heraeus, Minifuge T VWR International, Darmstadt, Germany 
Heraeus, Biofuge primo Kendro Laboratory Products, Hanau, Germany 
Heraeus, Sepatech Biofuge A Heraeus Sepatech, München, Germany 
ELISA-Reader:  
Tecan, GENios Plus Tecan, Crailsheim, Germany 
Confocal microscopy 
LSM501 META laser 
 
 CarlZeiss, Jena, Germany (Leica) 
Leica SP5 AOBS 
Real-Time  System: 
Leica 
Light Cycler 480, Roche Roche Diagnostics, Mannheim, Germany 
Chameleon Ultra-II two-photon 
Other Equipments: 
(Coherent) 
Nanodrop PEQLAB Biotechnology, Erlangen, Germany 
Cryostat CM 3000 Leica Microsystems, Bensheim, Germany 
Homogenizer ULTRA-TURRAX  IKA GmbH, Staufen, Germany 
Microtome HM 340E Microm, Heidelberg, Germany 
pH meter WTW WTW GmbH, Weilheim, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Vortex Genie 2™ Bender & Hobein AG, Zürich, Switzerland 
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Water bath HI 1210 Leica Microsystems, Bensheim, Germany 
qRT-PCR syber green  LC-480 Roche, Mannheim, Germany 
If not stated otherwise, all other reagents were of analytical grade and are commercially available 
from Invitrogen and Sigma-Aldrich.  
3.2 Experimental procedures 
3.2.1 Animal models 
The experiments were performed in Germany and Italy according to the Italian and German 
animal care and were approved by local government authorities. Balb/cAncrl, mice were obtained 
from Charles-Rriver, Germany. Balb/cAncrl Ancrl mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany), and NPHS2-rtTA;tetO-Cre;Rosa26-TomatoRedGFP and 
hNPHS2.rtTA;TetO.Cre;iDTR mice were obtained from Prof.Tobias Hüber (132) (University of 
Freiburg, Germany) and Prof. Waismann A (133) (University of Mainz), Pax2.rtTA;TetO.Cre;mT/mG 
mice were developed by crossing the mT/mG reporter strain B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-
tdTomato,-EGFP)Luo/J  from Prof. Romagnani P. (University of Florence, Italy) (27). Mice were housed in 
groups of five mice in standard housing condition with a 12-hour light/dark cycle. Cages, nest lets, 
food, and water were sterilized by autoclaving before use and mice were allowed to unlimited 
access to food and water. 
3.2.2 Experimental design 
In this experimental thesis, several mouse disease models have been used, which are described in 
more detail within this section: 
A) CXCL12 blockade in ADR-induced nephropathy  
B) Therapeutic blockade of CXCL12 in an ADR-induced nephropathy mouse model 
C) NPHS2.rtTa:TetO.Cre;iDTR;mT/mG-induced nephropathy and CXCL12 blockade 
D) ADR-induced nephropathy and CXCL12 blockade in an induced PAX2 lineage-tracing genetic 
mouse model 
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A) CXCL12 blockade in Adriamycin-induced nephropathy  
 
Figure 10. Treatment protocol A 
ADR nephropathy was induced in 6-weeks old Balb/cAncrl mice, which received a single tail vein 
injection of 13.4mg/kg doxorubicin hydrochloride (Pharmacia&Upjohn, Erlangen, Germany) on day 
0. Mice received three subcutaneous injections of NOX-A12 (13.4mg/kg) or revNOX-A12 in 5% 
sucrose (B.Braun, Melsungen, Germany). Group size was n=6-8 mice in each experiment. After 7 
days plasma and urine samples were collected before sacrifice by cervical dislocation and kidney 
tissues harvested. The kidneys were divided into three parts. One part was immediately flash frozen 
in liquid nitrogen and then further stored at -800C for protein isolation and cryo sections, the second 
part was collected in RNA later solution (Ambion, CA, USA) and stored at -200C for RNA isolation and 
the third part of the kidney was kept in formalin to fix the tissue before embedding in paraffin for 
histological analysis.  
B) Therapeutic blockade of CXCL12 in an adriamycin -induced nephropathy model 
 
Figure 11. Treatment protocol B 
ADR nephropathy was induced in 6-week old Balb/cAncrl mice, which received a single tail vein 
injection of 13.4mg/kg doxorubicin hydrochloride (Pharmacia&Upjohn, Erlangen, Germany) to 
induce a nephropathy. Mice received three subcutaneous injections of NOX-A12 (13.4mg/kg) or 
revNOX-A12 in 5% sucrose (B. Brown) on day 7 until day 14. Group size was n=6-8 mice in each 
experiment. At the end of the study, plasma and urine samples were collected before sacrifice by 
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cervical dislocation and kidney tissues harvested. The kidneys were divided into three parts, as 
described before.  
C) ADR-induced nephropathy and CXCL12 blockade in an induced Pax2.rtTA;TetO.Cre;mT/mG 
lineage-tracing genetic mouse model 
 
Figure 12. Treatment protocol C 
Reporter Pax2.rtTA;TetO.Cre;mT/mG  transgene recombination was induced at 6 weeks of age by 
administration of doxycycline hyclate (2 mg/ml, Sigma-Aldrich) in drinking water additioned of 2.5% 
sucrose (Sigma-Aldrich), for 10 days. Pax2.rtTA;TetO.Cre;mT/mG induced at the age of 8-9 week-old 
male and female old mice received by two successive tail veil injections of 18 mg/kg doxorubicin 
hydrochloride (Sigma-Aldrich) on the day -7 and day 0. Mice received subcutaneous injections with 
13.4mg/kg of the CXCL12 inhibitor NOX-A12 (NOXXON, Berlin, DE) in 5% sucrose (vehicle) or control 
CXCL12 inhibitor revNOX-A12 (NOXXON, Berlin, DE), thrice a week. Mice were sacrificed at the end 
of the experimental period of 33 days (n=8), kidneys were collected, incubated in 4% PFA in PBS for 2 
hours at 4°C followed by immersion in a 15% sucrose solution in PBS for 2 hours at 4°C and 
subsequently in a 30% sucrose solution in PBS overnight at 4°C, then frozen kidneys were collected 
as detailed above and analyzed by confocal microscopy. At least 4 healthy mice were included in 
each experiment. Urinary albumin and creatinine ratio was evaluated on spot urine using the system 
described below. 
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D) NPHS2;TetO.Cre;iDTR/mT/mG-induced nephropathy and CXCL12 blockade 
 
Figure 13. Treatment protocol D 
hNPHS2.rtTA;TetO.Cre;iDTR mice (Podocin-iDTR received doxycycline hydrochloride (Sigma-Aldrich) 
via the drinking water (2mg/ml with 5% sucrose, protected from light) during pregnancy and nursing 
to induce transgene recombination. To increase induction efficiency, the mice received doxycycline 
(2mg/ml) orally from P6 to P18 three times per week. Diphtheria toxin (DT) (Sigma-Aldrich) was 
injected once intraperitoneally, to induce mild podocyte depletion with DT 2ng/g body weight. For 
blocking CXCL12, mice received 13.4mg/kg of the CXCL12 inhibitor NOX-A12 (NOXXON) in 5% 
sucrose (vehicle) or control CXCL12 inhibitor revNOX-A12 (NOXXON) subcutaneously thrice a week. 
On day 7, mice were euthanized by cervical dislocation, and kidneys harvested. Blood and urine 
were collected before sacrifice to evaluate the functional parameters of the kidney damage. Kidneys 
were harvested as described above. 
3.3 CXCL12 inhibitor 
Spiegelmers were modified with 40Kd branched polyethylene glycol (PEG) at 5’-end. The antagonist 
binds CXCL12 with sub-nanomolar affinities. All spiegelmers were dissolved in isotonic 5% glucose (B. 
Brown). 
Sequences: 
 NOX-A12 (CXCL12 antagonist )  
5’GGCGACAUUGGUUGGGCAUGAGGCGAGGCCCUUUGAUGAAUCCGCGGCCA-3’ 
 revNOX-A12 (control antagonist) 
5’GCAUGGACUGAUCCUAGUCGGUUAUUAGAUCUAGUGUGGUGCG-3’ 
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3.4 Blood and urine sample collection 
Urine samples were collected using the approved methods. Collected urine was stored at -
200C until used for further biochemical analysis. At the end of the study blood samples were 
collected by retro-orbital bleeding technique under isoflurane anesthesia in microcentrifuge tubes 
containing EDTA (10μl of 0.5M solution per 200μl of blood). Samples were centrifuged at 8000 rpm 
for 5 minutes and plasma was separated and stored at -200C until used for analysis. BUN levels were 
measured by BUN Standard FS (DiaSys Diagnostic Systems). 
3.5 Urinary albumin to creatinine ratio 
Mouse Albumin ELISA Quantification Set (Bethyl, Montgomery, TX), and Creatinine Assay kit 
were used as per manufacturer’s instructions. Mouse albumin is an indirect competitive ELISA 
designed to monitor urinary albumin. In the assay procedure, sample and rabbit anti-murine 
albumin capture antibody are added to albumin-coated wells. The antibody interacts and binds with 
the albumin immobilized to the stationary phase or with albumin in the fluid phase, hence the 
notion of competitive binding. Generally, albumin levels in urine samples from FSGS mice were quite 
high, therefore, urine samples were diluted 1000 times (receipt provided by the kit) before 
estimation. In short, primary antibody rabbit anti-murine albumin were added into the respective 
wells of an NUNC 96well maxisorbp (Sigma-Aldrich) plate (pH 9.6 carbonate-bicarbonate buffer 
1:100) and incubated overnight at 4°C. The plate was washed 3 times (TRIS-NaCl 1x buffer+ 0.05% 
Tween 20). The coated plate was incubated for 1 hour at room temperature (RT) with blocking 
buffer (TRIS-NaCl 1times + BSA 1%) to reduce the aspecific bindings. The plate was washed 3 times. 
Diluted samples/standards were added and incubated at room temperature (RT) for 60 minutes. 
After incubation, each well was washed 3 times with wash buffer. Anti-rabbit HRP conjugated 
detection antibody) was added and the plate was incubated in dark for further 60 minutes. After 
HRP-conjugate incubation, each well was washed 3 times with wash buffer and incubates for 5-10 
minutes in the dark at RT. TMB reagent (freshly prepared by mixing equal volumes of two substrate 
reagents) was added and incubated in dark until color reaction was completed followed by addition 
of 50µl stop solution (1N H2SO4). The absorbance was read at 450 nm within 10 minutes after adding 
the stop solution with an ELISA plate reader. The albumin content in each sample was determined 
using the equation of regression line generated by plotting absorbance of different standards against 
their known concentrations.  
Urinary creatinine and plasma creatinine levels were measured using Jaffe´s enzymatic 
reaction using a Creatinine FS kit (DiaSys Diagnostic system, GmbH, Holzheim, Germany). Urine 
samples were diluted 10 times with distilled water. Different dilutions of the standard were 
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prepared using the stock provided with the kit. Working mono-reagent was prepared by mixing 4 
parts of reagent 1 (R1) and 1 part of reagent 2 (R2) provided with the kit. Then, 10μl of each diluted 
sample and standard was added into a 96 well plate with a flat bottom (Nunc maxisorb plate). The 
mono-reagent (200µl) was added to each well, and immediately after 1 minute of incubation, the 
absorbance of the reaction mixture was measured at 492nm using an ELISA plate reader. This was 
repeated after 1 and 2 minutes of additional incubation. The change in absorbance (Δ A) was 
calculated as Δ A = [(A-2 –  A-1) sample or standard] – [( A2 – A-1) blank]. And creatinine content of 
samples was calculated as Creatinine (mg/dl) = ΔA sample /ΔA standard * Concentration of standard 
(mg/dl)Urinary albumin to creatinine ratio was calculated after converting values for albumin and 
creatinine to similar units (mg/dl). Albumin content for each sample calculated (mg/dl) was divided 
by creatinine content (mg/dl) for the same sample. 
3.6 Immunostaining and confocal imaging 
All immunofluorescent studies were performed on five micrometer-thick frozen sections and 
analyzed with an LSM510 META laser confocal microscope (Carl Zeiss, Jena, Germany). Five µm thick 
frozen sections were cut and fixed in cold formalin (4% in PBS or Saline) for 20 minutes and washed 
for 5 minutes in PBS. Specific blocking buffer was prepared in PBS 1x+ 3% BSA+ diluted serum host of 
the secondary antibody and added. Sections were incubated for 30 minutes at room temperature. 
Afterwards, sections were incubated with diluted primary antibody for 15 minutes at 37°C followed 
by 1 hour at 4 °C. After washing for 5 minutes with PBS 1x, 200µl of the specific secondary antibody 
(diluted 1:1000) was added and the sections incubated for 30 minutes in the dark at room 
temperature. At the end of the incubation with the secondary antibody, the sections were washed 
for 5 minutes followed by the second staining performed as previously described. The nuclei staining 
were performed using DAPI or To-Pro-3 (1:1000 Life Technologies, Darmstadt, Germany). The 
following primary antibodies were used: pig anti-mouse nephrin (1:100, Acris Antibodies, Herford, 
Germany), rabbit anti-mouse WT-1 (1:25, Santa Cruz Biotechnology, Santa Cruz, CA), anti-rabbit 
CXCL12 (1:100; R&D, Minneapolis, MN), NICD-1 C-20 rabbit goat polyclonal IgG (1:10, Santa Cruz, 
USA), NICD3 rabbit polyclonal (1:10, ABCAM, UK), anti-SYN (mAb, G1D4, Progen, Heidelberg, 
Germany). H3-Ser10 (Cell Signaling, Danvers, MA), α-tubulin (Sigma-Aldrich). Secondary antibodies 
were obtained from Molecular Probes (Life Technologies, Monza, Italy) using different fluorochrome 
of the spectrum, 643, 544, 488nm. Immunofluorescent staining were evaluated using LSM 510 
confocal microscope and LSM software (Carl Zeiss, Germany). Confocal microscopy was performed 
on 10μm sections of renal frozen tissues by using a Leica SP5 AOBS confocal microscope (Leica) 
equipped with a Chameleon Ultra-II two-photon laser (Coherent). Nuclei were counterstained with 
To-pro-3 (1:1000 Life Technologies) or DAPI (Life Technologies 1:1000). The degree of 
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glomerulosclerosis was assessed by observing 50 randomly selected glomeruli from each mouse 
kidney from PAS-stained kidney sections under a light microscope (Leitz DMR, Leica Microsystems, 
Bensheim, Germany). These glomeruli were then further classified as having no lesions, segmental 
lesions (<50 of glomerulus) or global lesions (>50% of glomerulus). Cellular crescents were assessed 
separately when more than a single layer of PECs was present around the inner circumference of BC.  
3.7 Periodic acid-Schiff staining 
For immunohistological studies one part of each kidney from each mouse was fixed in 
formalin (4% in PBS or Saline) overnight and processed using tissue processors (Leica) and paraffin 
blocks were prepared. 2µm thick paraffin-embedded sections were cut. De-paraffinization was 
carried out using xylene (3 * 5 minutes) followed by re-hydration by incubating the sections in 100% 
absolute ethanol (3 * 3 minutes), 95% ethanol (2 * 3 minutes) and 70% ethanol (1 * 3 minutes) 
followed by washing with distilled water (2 * 5 minutes). Rehydrated sections were incubated with 
Periodic acid (2% in distilled water) for 5 minutes followed by washing with distilled water  for 5 
minutes. Then sections were incubated with Schiff solution for 20 minutes at room temperature 
followed by washing with tap water for 7 minutes and counter staining with Hematoxylin solution 
(1* 2 minutes). This was followed by washing with tap water (1* 5 minutes) and finally sections were 
dipped in alcohol 90% and dried and closed with cover slips. For routine histology and morphometric 
analysis, 4µm sections were stained with the periodic acid-Schiff (PAS) reagent. For 
immunohistochemistry, sections were deparaffinized, rehydrated, transferred into citrate buffer, 
and either autoclaved or microwave-treated for antigen retrieval and processed as described (134). 
The frozen tissues were fixed in paraformaldehyde 4% for 2 hours, then 2 hours in 15% 
Sucrose/PBS1x solution and overnight in 30% Sucrose/PBS 1x solution at 4°C. 
Table 2. Representative images of glomerular lesions  
 
Score Lesion in Glomeruli  
No lesion (0)  None 
Segmental Lesion (1) ≤ 50 %  
Global Lesion (2) ≥ 50 % 
All sections in each group were quantified as a percentage of glomeruli with each score (mean ± 
SEM).  
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3.8 Podocyte loss quantification 
Podocyte quantification in Pax2.rtTA;TetO.Cre;mT/mG mice we quantified: 1) the percentage 
of podocyte loss (P ) = 100 – mean of n° of total podocyte loss (green/blue + red/blue cells) at day 33 
in proteinuric mice/mean of n° of total podocytes in healthy mice x 100; 2) the percentage of newly 
generated podocytes (P ) = mean of n° of regenerated podocytes (red/blue new cells)/mean of n° of 
total podocytes at day 33 in proteinuric mice x 100 – mean of n° of regenerated podocytes (red/blue 
cells)/mean of n° of total podocytes in healthy x 100; 3) total percentage of lost podocytes (ablated 
podocytes, P ) = P  + Podocyte  ablated and loss new.  The percentage of regenerated podocytes over 
lost podocytes was thus = P /P x 100.  Similar formulas were used in Pax2.rtTA;TetO.Cre;mT/mG 
mice, where podocytes were quantified as the number of SYN+ or WT-1+ cells per glomerular 
section in 15 glomeruli of at least four sections for each mouse counted by two independent 
observers. 
3.9 Cell culture studies  
Isolation and culture of human renal progenitors CD24+CD133+ 
RPCs were characterized and isolated from human renal biopsies as described (28, 45, 88, 
135). In brief, kidney biopsies were processed and sieved for isolating glomeruli (60, 80, and 150 
mesh). During this process, the glomeruli were separated from the tubules through graded mesh 
screening. To enrich the number of capsulated glomeruli, non-enzymatic digestion was 
performed. The glomerular suspension was collected and plated on fibronectin-coated dishes 
(10μg/ml; Sigma-Aldrich). After 4 to 5 days in culture, isolated glomeruli adhered to the 
plate resulting in cellular outgrowth. Glomeruli were detached, and the cellular outgrowth 
was cultured as a bulk. The cells were cultured with Endothelial Cell Growth Medium (EGM-
MV) 20% FBS (Hyclone, Logan, UT) media and they were checked for simultaneous 
expression of the surface marker CD133 and CD24 by flow cytometer analysis. Generation of 
clones from CD24+CD133+ PECs was performed by limiting the dilution in fibronectin-coated 
96-well plates in EGM-MV 20% FBS. CD24+CD133+ PECs were also maintained in culture as a bulk, 
and routine cell passaging was performed. All experiments were performed using cells at least at 
passage 3. Cells were grown at 370C supplied with 5% CO2. Trypsin and EDTA (1:1 vol/vol) was used 
for splitting the cells. Cells were counted using a Neubauer chamber and the desired numbers of 
cells were used for experiments. 
RPCs for RNA extraction were seeded at a density of 10x105 cells/well in six-well plates in  
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Endothelial Cell Basal Medium (EBM) medium (LONZA, Basel, Switzerland) and grown overnight to 
the confluence. The cells were then incubated with 100nM human CXCL12 (Immunotools, 
Friesoythe, Germany), 1mg/ml NOX-A12 or revNOX-A12 and incubated at 37°C, 5% CO2 for 24 hours. 
For the proliferation/ viability assays, the human RPCs were seeded in 96-well plates (8000 
cells/well) and incubate at 37°C in EBM medium (LONZA). The RPCs were then incubated with 
100nM CXCL12, NOX-A12 1mg/ml or revNOX-A12m (NOXXON), 10µM of the γ-secretase inhibitor IX 
DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) that was obtained from 
Merck, KGaA, Darmstadt, Germany or their combination for 24 hours and CellTiter 96 Non-
Radioactive Cell Proliferation Assay (MTT assay) was performed (Promega, Madison, WI) according 
to the manufacturer’s instructions. Experiments were performed in quintuplicate.   
Differentiation of RPCs into podocytes 
Human RPC differentiation toward podocytes were obtained  as follow: RPCs were 
incubated in the podocyte differentiation medium VRAD (Dulbecco Eagle Modified Medium Ham f-
12 (DMEM-F12 )(LONZA) enriched  with: 10% FBS (Hyclone), All-trans-retinoic acid (ATRA) 100µM 
(Sigma-Aldrich) and 100nM Vitamin D-3 (Sigma-Aldrich) incubation for 48 hours with 37°C and 5% 
CO2 (27, 28, 135). During the differentiation, podocytes were incubated with: control EBM medium 
(LONZA), 10% Fetal Bovine serum (FBS) (Hyclone), VRAD medium with DMEM-F12 (Sigma-Aldrich) 
plus (All-trans retinoic acid, ATRA 100uM, Sigma-Aldrich) and 10µM Vitamin D3 (Sigma-Aldrich), 
100nM CXCL12 (r-human, Immunotools, Friesoythe, Germany), NOX-A12 1mg/ml or revNOX-A12 or 
a combination of both. Total mRNA was isolated from the podocytes and analyzed for podocyte 
expression levels of the principal podocyte markers: nephrin, CD2AP and podocalyxin for the 
podocyte cytotoxicity assay, podocytes were obtained as described before, and incubated for 24 
hours with: doxorubicin 10µM, CXCL12 100nM (Immunotools), NOXA-12 1mg/ml, revNOX-A12 
1mg/ml and DAPT 10µM (Merck) or a combination of both. LDH assay was performed (Roche, 
Switzerland) according to the manufacturer’s instructions. Experiments were performed in 
quintuplicate. 
Preparation of necrotic supernatants from podocytes 
For the podocyte necrotic supernatant (NS) proliferation assay, 2500cells/ml podocytes 
were obtained as described before and 3 cycles of heating from -80°C to 60°C in DMEM F-12 
medium (Sigma-Aldrich) were performed to get NS. Human RPCs were incubated for 24 hours with: 
30µL/mL NS plus 1mg/ml NOX-A12, revNOXA-12 or CXCL12 100nM and DAPT 10µM (Merck).  MTT 
assay was performed (Promega) according to the manufacturer’s instructions. Experiments were 
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performed in quintuplicate. For the podocyte cytotoxicity assay, podocytes were obtained as 
described before and incubated for 24 hours with: doxorubicin 10µM, CXCL12 100nM 
(Immunotools), NOXA-12 1mg/ml, revNOX-A12 1mg/ml and DAPT 10µM (Merck) or a combination 
of both. LDH assay was performed (Roche, Switzerland) according to the manufacturer’s 
instructions. MTT assay was performed (Promega, Madison, WI) according to the manufacturer’s 
instructions. Experiments were performed in quintuplicate.  
Cell freezing and thawing 
At earlier passages large amounts of cells were grown under standard culture conditions and 
were frozen for future use. Cells to be frozen were detached from the culture plates and counted 
using the Neubauer’s chamber. One million (106) cells were centrifuged under sterile conditions for 5 
minutes at 1000 rpm. The cell pellet was maintained on ice and carefully re-suspended in cold 
freezing medium (90% respective culture medium and 10% DMSO) by pipetting the suspension 
repeatedly up and down. One ml aliquots were quickly dispensed into freezing vials. The cells were 
located in the freezing chamber at –800C overnight. The next day, all aliquots were transferred to 
liquid nitrogen. In order to thaw cells, a frozen vial was removed from liquid nitrogen and put into a 
water bath at 370C for 5 minutes. The cells were then resuspended in 10ml of warm complete 
growth medium and transferred into new culture plates. After 12 hours, cells were observed under 
the microscope and the medium was changed once more 
3.10 Protein isolation and western blotting  
Protein from kidney tissues as well as cells were extracted using lysis buffer (Tris-HCl 50mM, 
NaCl 150mM, sodium orthovanadate 100μM, sodium deoxycholate 0.5%, NP40 4%, Triton X-100 2%, 
EDTA 5mM, sucrose 300mM, and Roche protease inhibitors). Total cellular extracts were prepared in 
protein lysis buffer (Tris 10mM, NaCl 10mM, ethylenediaminetetraacetic acid 10mM, HEPES 1mol/l, 
glycerol 20%, MgCl2 1 mol/l, dithiothreitol 1mol/l, Triton, 10% sodium fluoride 1mol/l, and Roche 
protease inhibitors). After determination of protein concentrations, 50μg of the kidney protein or 
10μg of protein extracted from cells was mixed with 5 × sodium dodecyl sulfate loading buffer 
(100mmol/l Tris-HCl, 4% sodium dodecyl sulfate, 20% glycerol, and 0.2% bromophenol blue) for 
western blot analysis. Samples were heated at 95°C for 5 minutes. Proteins were separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to a polyvinylidene 
difluoride membrane. Nonspecific binding to the membrane was blocked for 1 hour at room 
temperature with 5% bovine serum albumin in tris-buffered saline buffer (20mmol/l Tris-HCl, 
150mmol/l NaCl, and 0.1% Tween 20). The membranes were incubated overnight at 4°C with 
primary antibodies, goat antibody against mouse NICD1, NICD2 and, NICD3 (ABCAM, UK) and rabbit 
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antibody against ß actin (Cell signaling). Secondary antibodies were a peroxidase-conjugated donkey 
anti-goat IgG (Dianova, Hamburg, Germany) and an anti-rabbit IgG (Cell signaling, and β-actin (Cell 
signaling), followed by incubation with the secondary antibody anti-biotin or anti-rabbit IgG labeled 
with HRP. Immunostained bands were detected. 
3.11 RNA isolation from cells and tissue 
At the end of the experiment, cells were harvested under sterile conditions for RNA isolation. 
Immediately after kidney isolation, a small piece of a kidney from each mouse was preserved in RNA-
later (Ambion, CA, USA) and stored at -200C until processed for RNA isolation. RNA isolation was 
performed using RNA isolation kit from Ambion according to the protocol provided. The harvested 
cells were washed two times with sterile PBS and centrifuged. The supernatant was discarded and 
the pellet was resuspended in 350μl lysis buffer containing 10μg/ml beta-mercaptoethanol and 
frozen at –80 °C until RNA isolation. Tissues (30mg) preserved in RNA-later were homogenized using 
a blade homogenizer for 30 seconds at 4°C in lysis buffer (600μl) containing β-mercaptoethanol 
(10μl/ml). During RNA isolation, the samples were thawed and 350μl of 70% ethanol diluted in 1% 
diethyl pyrocarbonate-treated water (DEPC water) was added to the samples and mixed well. This 
mixture was then loaded onto RNeasy mini columns held in 2ml collection tubes and centrifuged at 
12000 g for 15 seconds. The flow-through was discarded and the columns were loaded with 700μl of 
Wash buffer I and centrifuged at 12000 g for 15 seconds. The collection tubes were discarded 
together with the flow-through and the columns were transferred to fresh 2ml collection tubes. 
500μl of Wash Buffer II was pipetted onto the column and centrifuged at 12000 xg for 15 seconds, 
and the flow-through was discarded. This step was repeated and the column was rendered dry by 
centrifugation and placed into a 1.5ml fresh collection tube. Then, 40μl of RNase-free water was 
pipetted directly on the silica-gel membrane and was centrifuged to collect the RNA solution. 
Isolated RNA was measured, checked for purity and stored at -800C. 
RNA quantification and purity check  
The isolated RNA samples were quantified using a Nanodrop (PEQLAB Biotechnology GMBH, 
Erlangen, Germany). The ratio of optical densities at 260 nm and 280 nm is an indicator for RNA 
purity (indicative of protein contamination in the RNA samples). Only samples with a ratio of 1.8 or 
more were considered to be of acceptable quality. 
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3.12 cDNA synthesis and real-time PCR 
The RNA samples, isolated according to procedures described above, were processed for 
cDNA conversion using reverse transcriptase II (Invitrogen, Karlsruhe, Germany). RNA samples were 
diluted in DEPC water to a concentration of 2μg / 30μl. A master mix was prepared with the 
following reagents: 9μl of 5 x buffer (Invitrogen, Karlsruhe, Germany), 1μl of 25mM dNTP mixture 
(Amersham Pharmacia Biotech, Freiburg, Germany), 2μl of 0.1M DTT (Invitrogen, Karlsruhe, 
Germany), 1μl of 40U/μl RNasin (Promega, Mannheim, Germany), 0.5μl of 15μg/ml linear acrylamide 
(Ambion Ltd, 36 Cambridgeshire, UK), 0.5 μl of Hexanucleotide (Roche, Mannheim, Germany), 1μl of 
Superscript (Invitrogen, Karlsruhe, Germany) or ddH2O as a control. The master mix was made to a 
volume of 13.2μl and added to 1μg / 20μl RNA samples were taken in separate DEPC treated 
microcentrifuge tubes, which were mixed and placed at 42°C on a thermal shaker incubator for 1 
hour. After 1 hour, the cDNA samples were collected and placed at -20°C until use for RT-PCR 
analysis. The cDNA samples prepared as described above were diluted 1:10 for real-time 
polymerase-chain-reaction (RT-PCR). Two μl of diluted cDNA samples was mixed with SYBR green 
master mix (10μl), forward primer (0.6μl) and, reverse primer (0.6μl), both specific for the gene of 
interest, Taq polymerase (0.16μl) and distilled water (6.64μl). The RT-PCR was performed using Light 
Cycler480. Pre-incubation was carried out for 5 minutes at 950C to activate the polymerase and 
complete denaturation of cDNA samples. cDNA was amplified for 45 cycles, each comprising of 15 
seconds incubation at 950C and 45 seconds incubation at 600C. The melting curve was set for initial 
950C for 5 seconds followed by 650C for 1 minute with continuous heating. The RT-PCR of the 
reference gene (18S rRNA) was carried out under similar conditions. The CT values were calculated 
using the Light Cycler480 and the results were normalized with respect to the reference gene 
expression. In all cases controls consisting of ddH2O were negative for target or reference genes. All 
designed SYBR green primers for all genes evaluated were obtained from Metabion (Metabion, 
Martinsried, Germany). 
3.13 Statistical analysis 
Data are presented as mean  SEM. A comparison of groups was performed using paired 
Mann-Withney U to compare two groups or one-way ANOVA with posthoc Bonferroni`s correction 
was used for multiple comparisons. A value of p < 0.05 was considered to indicate statistical 
significance. 
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Table 3. Human Primers for RT 
 
Target Primer sequence  
Notch-1 Forward Primer  5’-3’ GTGAACTGCTCTGAGGAGATC 
 Reverse Primer   5’-3’ GGATTGCAGTCGTCCACGTTGA 
Notch-2 Forward Primer  5’-3’ GTGCCTATGTCCATCTGGATGG 
 Reverse Primer   5’-3’ AGACACCTGAGTGCTGGCACAA 
Notch-3 Forward Primer  5’-3’ TACTGGTAGCCACTGTGAGCAG 
 Reverse Primer   5’-3’ CAGTTATCACCATTGTAGCCAGG 
Dll-1 Forward Primer  5’-3’ TGCCTGGATGTGATGAGCAGCA 
 Reverse Primer   5’-3’ ACAGCCTGGATAGCGGATACAC 
Jag-1 Forward Primer  5’-3’ TGCTACAACCGTGCCAGTGACT 
 Reverse Primer   5’-3’ TCAGGTGTGTCGTTGGAAGCCA 
Jag-2 Forward Primer  5’-3’ GCTGCTACGACCTGGTCAATGA 
 Reverse Primer   5’-3’ AGGTGTAGGCATCGCACTGGAA 
Hey-1 Forward Primer  5’-3’ TGTCTGAGCTGAGAAGGCTGGT 
 Reverse Primer   5’-3’ TTCAGGTGATCCACGGTCATCTG 
Hes-1 Forward Primer  5’-3’ GGAAATGACAGTGAAGCACCTCC 
 Reverse Primer   5’-3’ GAAGCGGGTCACCTCGTTCATG 
Nephrin Forward Primer  5’-3’ GTCTGCACTGTCGATGCCAATC 
 Reverse Primer   5’-3’ CCAGTTTGGCATGGTGAATCCG 
Podocin Forward Primer  5’-3’ CTGTGAGTGGCTTCTTGTCCTC 
 Reverse Primer   5’-3’ CCTTTGGCTCTTCCAGGAAGCA 
Podocalyxin Forward Primer  5’-3’ CCTGAACCTCACAGGAAACACC 
 Reverse Primer   5’-3’ TGGAACAGATGCCAGCCGTATG 
CD2AP Forward Primer  5’-3’ CCAAAGCCTGAACTGATAGCTGC 
 Reverse Primer   5’-3’ GGACTTGTGGAGCTGCTGGTTT 
18s Forward Primer  5’-3’ GCAATTATTCCCCATGAACG 
 Reverse Primer   5’-3’ AGGGCCTCACTAAACCATCC 
List of abbreviations sees Abbreviations section 9  
 
 
 
Materials and Methods                                                                                                            
39 
 
Table 4. Murine Primers for RT 
 
Target Primer sequence 
Notch-1 Forward Primer  5’-3’ GCTGCCTCTTTGATGGCTTCGA 
 Reverse Primer   5’-3’ CACATTCGGCACTGTTACAGCC 
Notch-2 Forward Primer  5’-3’ CCACCTGCAATGACTTCATCGG 
 Reverse Primer   5’-3’ TCGATGCAGGTGCCTCCATTCT 
Notch-3 Forward Primer  5’-3’ GGTAGTCACTGTGAACACGAGG 
 Reverse Primer   5’-3’ CAACTGTCACCAGCATAGCCAG 
Dll-1 Forward Primer  5’-3’ GCTGGAAGTAGATGAGTGTGCTC 
 Reverse Primer   5’-3’ CACAGACCTTGCCATAGAAGCC 
Jag-1 Forward Primer  5’-3’ TGCGTGGTCAATGGAGACTCCT 
 Reverse Primer   5’-3’ TCGCACCGATACCAGTTGTCTC 
Jag-2 Forward Primer  5’-3’ CGCTGCTATGACCTGGTCAATG 
 Reverse Primer   5’-3’ TGTAGGCGTCACACTGGAACTC 
Hey-1 Forward Primer  5’-3’ CCAACGACATCGTCCCAGGTTT 
 Reverse Primer   5’-3’ CTGCTTCTCAAAGGCACTGGGT 
Hes-1 Forward Primer  5’-3’ GGAAATGACTGTGAAGCACCTCC 
 Reverse Primer   5’-3’ GAAGCGGGTCACCTCGTTCATG 
Nephrin  Forward Primer  5’-3’ CAGCGAAGGTCATAAGGGTC 
 Reverse Primer   5’-3’ CACCTGTATGACGAGGTGGA 
Podocin Forward Primer  5’-3’ CAGGAAGCAGATGTCCCAGT 
 Reverse Primer   5’-3’ TGACGTTCCCTTTTTCCATC 
CD2AP Forward Primer  5’-3’ CATCCCTCGTCTCCCATTTA 
 Reverse Primer   5’-3’ TATCCGAGTTGGGGAAATCA 
Synaptopodin  Forward Primer  5’-3’ GCCAGGGACCAGCCAGATA 
 Reverse Primer   5’-3’ AGGAGCCCAGGCCTTCTCT 
WT-1 Forward Primer  5’-3’ GGTTTTCTCGCTCAGACCAGCT 
 Reverse Primer   5’-3’ ATGAGTCCTGGTGTGGGTCTTC 
18s Forward Primer  5’-3’ GCAATTATTCCCCATGAACG 
 Reverse Primer   5’-3’ AGGGCCTCACTAAACCATCC 
List of abbreviations sees Abbreviations section 9 (Notch primers Niranjan T et al 2010) 
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4. Results 
4.1.Effects of podocyte-derived CXCL12 in a mouse model of specific podocyte depletion  
4.1.1. CXCL12 is a podocyte survival factor during a specific podocyte depletion model  
To answer the specific question about CXCL12 and podocyte survival we used specific 
podocyte depletion system NPHS2/rtTa-tetO-CMV/iCre/iDTR/TomatoRed (Podocin-iDTR/mT/mG) 
mice were obtained from our collaborator in Freiburg (132) that have a fluorescent reporter system 
endogenous green florescent protein(green)/endogenous red florescent protein(red) meaning that 
all podocytes express the human diphtheria toxin receptor (DTR) on their cell membrane after pre-
stimulation with the antibiotic doxycycline (methods section 2.2). Figure 15A illustrates a 
representative confocal microscopy image of a healthy doxycycline-induced Podocin-iDTR/mT/mG 
mouse to test the model efficiency (genome cartoon). After doxycycline-induced expression of the 
DTR, mice received a single injection of the human diphtheria toxin (DT) to induce podocyte 
depletion by DT toxicity followed by Diphtheria toxin nephropathy. Immediately after the induction 
of the disease, Podocin-iDTR/mT/mG mice were treated with the CXCL12 inhibitor NOX-A12 or the 
control compound revNOX-A12. (see methods part 2.2). The urinary albumin /creatinine ratio 
(UACR) showed a significant progression of the disease in mice that were treated with the CXCL12 
inhibitor compared to the inhibitor control (Figure 15B). Following blockade of CXCL12, blood urea  
nitrogen and creatinine levels were also significantly increased in Podocin-iDTR/mT/mG mice (Figure 
15C) indicating that CXCL12 acts as a survival factor for podocytes during Diphtheria toxin 
nephropathy. 
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Figure 15. CXCL12 is blocked aggravates Diphtheria toxin nephropathy. NHP2rtTA/Tet-ON-íCRE/ iDTR/mG/mG 
mice were induced to Diphtheria toxin nephropathy as described in methods section 2.2). Two groups of mice 
CXCL12 inhibitor NOX-A12) or control revNOX-A12 from day 0 until day 7. (A) Schematic of the genetic model 
of Podocin-iDTR/mT/mG mouse model of diphtheria toxin nephropathy and a representative IF of an induced 
mouse to check the efficiency of the system. (B, C) CXCL12 blockade increased UACR (B), BUN and creatinine 
(C) in the Diphtheria toxin nephropathy compared to the control group. The data are means ± SEM from 6-7 
animals per NOX-A12 group. *p<0.05 versus revNOX-A12 group. 
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4.1.2.  CXCL12 blockade aggravates diphtheria toxin-induced nephropathy renal pathology 
Next, we performed PAS staining on kidney sections to displayed the histopathology score. As 
illustrated in Figure 16A, NOX-A12 treatment increased the glomerular sclerosis score was 
aggravated  compared to the control group after 7 days. In particular, the percentage of global 
glomerular lesions increased when CXCL12 was inhibited, whereas the quantity of normal glomeruli 
and glomeruli with segmental lesions was reduced (Figure 16B).  
A 
 
B 
 
 
 
 
 
 
 
Figure 16: CXCL12 blockade increases the severity of Diphtheria toxin nephropathy. (A) Representative 
pictures of PAS- stained kidney sections in the DTN mouse model after CXCL12 blockade. (B) The glomerular 
injury score showed worsening of glomerular injury when CXCL12 was blocked compared to control. CXCL12 
blockade significantly increased the number of global glomerular lesions on day 7 during Diphtheria toxin 
nephropathy compared to the control group. The data are means ± SEM from 6-7 animals in each NOX-A12 
group, *p<0.05, **p<0.01 versus revNOX-A12group at day 7. Original magnification 400x. 
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4.1.3.  Podocyte numbers decreased after CXCL12 blockade in Diphtheria toxin 
nephropathy 
To determine the podocyte score I performed at the end of the study, IF staining for 
Nephrin/WT-1. The results showed that during Diphteria toxin nephropathy, inhibition of CXCL12 
reduced the number of podocytes compared to control (Figure 17B). The decreased number of 
podocytes was associated with decreased levels of total kidney mRNA for the podocyte-specific 
markers Nephrin, Podocin, Synaptopodin and CD2AP after NOX-A12 treatment during DTN (Figure 
17B).  
A                                B                       
 
 
 
 
 
 
 
Figure 17. Podocyte evaluation of Diphtheria toxin nephropathy. (A) CXCL12 blockade decreased the total 
number of Nephrin/WT-1 double positive cells per glomerulus on day 7 during Diphtheria toxin nephropathy 
compared to control revNOX-A12. (B) Blockade of CXCL12 in diphtheria toxin nephropathy reduced nephrin 
renal mRNA levels in the kidney. The data are means ± SEM from 6-7 animals in each NOX-12 treated group, 
*p<0.05 versus revNOX-A12 group at day 7.  
Finally, I determined the impact of the CXCL12 blockade on the survival of Podocin-
iDTR/iDTR mice, which were in homozygosis for the iDTR during Diphtheria toxin nephropathy. As 
shown in Figure 18, we observed a significant difference in the survival Kaplan-Maier analysis (Figure 
18A) on day 2 after Diphtheria toxin nephropathy onset was observed. During the first 2 days, more 
than 60% of the NOX-A12-treated Podocin-iDTR/iDTR mice died, whereas 40% of the remaining mice 
survived until sacrifice on day 7. These data indicate that Podocin-iDTR/iDTR mice in homozygosis 
loss more podocytes (more than 50%) after a single diphtheria  injection compared to Podocin-
iDTR/mT/mG mice and that these mice were much more susceptible to Diphtheria toxin 
nephropathy in combination with the CXCL12 blockade. Together, the data suggests that CXCL12 
produced by podocytes acts as an autocrine survival factor during glomerular injury. 
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Figure 18: Kaplan-Meier in Podocin-iDTR/iDTR mouse model of Diphtheria toxin nephropathy. In a 
homozygote Podocin-iDTR/iDTR mouse, I induced with diphtheria toxin injection a Diphtheria toxin 
nephropathy-DTN, CXCL12 blockade decreased the survival ratio more the 60% in the NOX-A12 group at day 2 
during Diphtheria toxin nephropathy compare to the control revNOX-A12. The data are means ± SEM from 10-
13 animals in each NOX-A12 group, *p<0.05 versus revNOX-A12 at day 2. 
4.2.CXCL12 is a podocyte survival factor by reduces mitotic catastrophe 
To further investigate the role of CXCL12 as podocyte survival factor, firstly human RPC-
derived podocytes were challenged in-vitro with the well-known death stimulus ADR in the presence 
of NOX-A12 or revNOX-A12. Secondly, to mimic the in-vitro system, we used a mouse model of ADR 
podocyte depletion. 
CXCL12 acts as a podocyte survival factor during adriamycin-induced cell death 
 
RPCs were differentiated into podocytes using VRAD medium for 48 hours as described in 
the methods. Following differentiation, RPCs were stimulated with ADR, a well-known podocyte 
cytotoxic drug, for 24 hours and measured the cytotoxic effect of ADR on podocytes using a 
photometric lactate dehydrogenase (LDH) assay. After establishing the optimal concentration of ADR 
for the LDH assay in-vitro, the CXCL12 podocytes pro-survival effect was investigated. Human RPCs 
were differentiated into podocytes in the presence of VRAD medium prior to the treatment with 
10µM ADR. As demonstrated in Figure 19B, ADR induced cell death in podocytes; however, this 
cytotoxic effect was significantly decreased following stimulation with CXCL12. Upon blockade of 
CXCL12 using the NOX-A12 spiegelmer, the cytotoxic effect of ADR on podocytes was reversed 
compared to control revNOX-A12. Taken together, CXCL12 was identified as an autocrine survival 
factor for podocytes.  
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Figure 19: Adriamycin induced podocyte death can be reduced by CXCL12 treatment in-vitro.  Treatment 
with CXCL12 significantly reduced ADR cytotoxicity; CXCL12 blockade by NOX-A12 restored this cytotoxic effect 
of ADR on podocytes. This data suggested that CXCL12 was a survival factor for podocytes. Data are means ± 
SEM  2-3 experiments, (§ p<0.01 normal podocyte versus ADR treatment), (* p<0.05 ADR treated podocyte 
versus ADR+CXCL12),(# p<0.05 ADR+CXCL12+NOX-A12 versus revNOX-A12 treated group) after 24h.  
 
4.2.1. CXCL12 acts as a podocyte survival factor during adriamycin-induced catastrophic 
mitotic cell death 
The functional significance of the constitutive release of CXCL12 by podocytes is still not fully 
clear. This raises the question of how CXCL12 acts as a survival factor for podocytes. Reports by 
Lasagni et al. and Mulay et al, (42, 64, 136) have shown that after an ADR-induced podocyte injury, 
podocytes detach or die via catastrophic mitosis (CM). Further work has reported an involvement of 
the Notch signaling pathway in CM activation(64). However, the role of CXCL12 during podocyte CM 
has not been investigated before; therefore, human podocytes were exposed to ADR with or 
without CXCL12 in the presence of either the active or inactive CXCL12 inhibitor. Moreover, the 
Notch inhibitor DAPT was used as a control. IF staining was performed to study the catastrophe 
mitosis (CM). CM was assessed by a double IF of histone H3 Serine 10 phosphorylated (H3-Ser10) a 
maker of CM activation (green), α-tubulin as a cytoskeleton integrity marker (red) and the 
chromatin-nuclear staining To-pro-3 (blue) (Figure 20). As illustrated in Figure 20-panel 1, human 
RPC showed a normal mitotic spindle and well-divided chromosomes. Mature podocytes, on the 
other hand, did not proliferate (Figure 20-panel 2), only when ADR was added into the medium and 
aberrant chromosomal division occurred (Figure 20-panel 3). Interestingly, following the addition of 
CXCL12 into the medium prevented such aberrant nuclear divisions(Figure 20-panel 4). Upon CXCL12 
blockade using NOX-A12, CM started again in comparison to the control inhibitor (Figure 20-panel 5-
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6). As expected, inhibition of Notch signaling with DAPT restored the normal podocyte structure 
(Figure 20-panel 7). However, combined treatment of DAPT and CXCL12 had no additive effect on 
CM (Figure 20-panel 8) as well as adding the CXCL12 inhibitor and control revNOX-A12 alone had no 
effect on preventing cathastrophic mitosis (Figure 20-panel 9-10). This data indicated that CXCL12 
inhibition accelerated the podocytes loss via catastophic mitosis. Thus, intrinsic CXCL12 is a podocyte 
survival factor during toxic injury-induced CM of podocytes.  
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Figure 20. CXCL12 reduces  catastrophic mitosis in-vitro. Immunostaining of podocytes for H3-Ser10 in green. 
Tubulin staining marks the mitotic spindle in red. To-pro-3 marks the chromatin in blue. Note that RPCs 
proliferate by forming normal mitotic spindles and appropriate chromosomal alignment in the anaphase plate 
in between the spindles (control) (1). Mature podocytes (2) do not proliferate in culture but ADR induced 
aberrant chromosomal division and mitotic catastrophe leading to cell death (3). This process is inhibited by 
CXCL12 (4). CXCL12 blockade induced CM (5) compared with the control inhibitor treatment (6). Podocytes 
were protected from CM in the presence of the Notch pathway inhibitor DAPT (8). The combination of CXCL12 
and DAPT had no additive effects on CM (8).  Treatment of NOX-A12 and revNOX-A12 had no protective 
effects on CM (9-10). Representative images, original magnification 1000x (scale bar 10µm). 
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4.3.The effect of CXCL12 during a murine model of Adriamycin-induced nephropathy 
In this section, I used a Balb/c mouse model of FSGS to investigate the effect of podocyte’s 
derived CXCL12. FSGS can be pharmacologically induced via ADR tail vein injection (see methods 
2.2). The disease developed within a few days after the induction of AN. This model was reliable, fast 
and the injury could be modulated in a dose-dependent manner.  
4.3.1. Podocytes are the major source of CXCL12 during focal segmental glomerular 
sclerosis 
In the past Darisipudi et al. (82) showed that during diabetic nephropathy, podocytes were the 
main source of CXCL12. Human podocytes were obtained from RPCs and IF staining was performed 
for the podocyte marker WT-1 (red), CXCL12 (green), and the blue nuclear marker DAPI (Figure 21A). 
The staining clearly showed that CXCL12 was produced from the podocytes (WT-1 and DAPI co-
stained, which appears as violet). To further identify the source of CXCL12 during AN, we performed 
an immune-staining for CXCL12 from kidneys of ADR-treated and non-treated (healthy) mice. 
Podocytes were positive for CXCL12 in the glomerulus even under healthy conditions (Figure 21A). 
During AN, podocytes expressed CXCL12 after 7 and 14 days, as shown in Figure 21B. IF co-staining 
showed that CXCL12 was mainly expressed in the cytosol of podocytes, whereas podocytes stained 
positively stained for WT-1 in the nucleus (Figure 21C). 
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A             B 
 
C 
 
Figure 21. CXCL12 is produced by podocytes. (A) RPCs derived podocyte IF staining: (red) WT-1, (Blue) DAPI, 
(green) CXCL12 IF (B) Using IHC staining for CXCL12 we showed CXCL12 production by podocytes in healthy 
and AN kidneys after 7 and 14 days. (C) Glomerular immune-fluorescent (IF) co-staining for CXCL12 (green) and 
WT-1 (red) and blue nuclei (To-pro-3) showed that CXCL12 was expressed in the cytosol of podocytes in 
healthy and ADR-injured mice. Representative images, the original magnification of A is 600x, B is 400x and C 
high magnification 600x. 
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4.3.2. Urine Albumin/Creatinine ratio and blood urea level in Adriamycin nephropathy  
During AN, the loss of podocytes was associated with UACR. After injecting mice with ADR, the 
UACR significantly increased on day 7 and 14 compared to control -treated healthy mice (Figure 
22A). As a consequence of AN, also, the BUN significantly increased on day 14 compared to control 
mice indicating a compromised excretory function of the kidney (Figure 22B).  
A       
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Figure 22. Characterization Adriamycin nephropathy mouse model. Wild-type Balb/c mice received an 
intravenous injection of ADR  (13.4mg/kg) to induce AN or PBS only as control and urine was collected on day 7 
and 14. (A) ADR induced an aggravation of kidney injury as demonstrated by increased urine 
albumin/creatinine ratio on day 7 and 14 during AN compared to healthy control group. (B) Plasma levels of 
urea (BUN) showed an evident increment at day 14 in the ADR group compared to PBS control. The data are 
means ± SEM from 6-7 animals per healthy group*p<0.05, **p<0.01, *** p<0.001 versus ADR group at day 7 
and 14. 
To further confirm the UACR data, I determined renal histomorphology after AN on day 7 
and 14. ADR injection induced a strong glomerulosclerosis in the kidney as demonstrated by PAS 
staining, in Figure 23A, and more segmental and global lesions were found in the ADR-treated mice 
compared to the healthy controls (Figure 23B). Thus, glomerular lesion score correlates with the loss 
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of podocytes following ADR treatment and the lesions are the major cause of the functional loss of 
the kidney.   
A 
 
B 
 
 
 
 
 
 
 
Figure 23. Renal histopathology of Balb/cAncrl mice with Adriamycin nephropathy. Mice were injected with 
ADR for 7 and 14 days and (A) PAS staining of the kidney sections carried out. (B) Segmental and global 
glomerular lesions were determined on day 14 during AN compared to control. The data are means ± SEM 
from 6-7 animals per healthy group. *p<0.05, **p<0.01, versus ADR group at day 7 and 14. Original 
magnification 400x. 
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4.3.3. Podocyte loss in adriamycin-induced focal segmental glomerular sclerosis 
ADR induced a reduction in the number of podocytes in the glomerulus. We performed an IF 
staining for the podocyte markers nephrin and WT-1. Also, I evaluated the staining with a semi-
quantitative analysis. The number of double positive cells (nephrin/WT-1) was significantly reduced 
after ADR injection compared to the control (Figure 24A). The loss of podocytes was a major feature 
during AN resulting in the severe loss of kidney functions. 
A 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Quantification of podocytes in Balb/cAncrl mice during Adriamycin nephropathy. ADR treatment 
caused a reduction in the number of podocytes in the glomeruli on day 7 and 14 compared to the healthy 
group. The data are means ± SEM from 6-7 animals per healthy group. (*p<0.05, **p<0.01, healthy mice group 
versus ADR group) at day 7 and 14.   
 
Renal mRNA expression levels of podocyte markers in total kidney during Adriamycin 
nephropathy 
To confirm the loss of podocytes during AN, mRNA expression levels of the classical 
podocyte markers in the kidneys were determined. In the ADR-treated group, a significant reduction 
in the mRNA expression levels of the podocyte markers was found, e.g.: Nephrin, Podocin, 
Synaptopodin and CD2AP on day 7 and 14 compared to the healthy controls (Figure 25).  
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Figure 25. Total kidney mRNA expressions in Adriamycin nephropathy. Wild-type Balb/c mice with AN. Total 
kidney mRNA from AN mice were analyzed for quantitative real-time PCR for a number of genes including 
Nephrin, Podocin, Synaptopodin, and CD2AP. The data are ± SEM from 6-7 animals in each group. (*p<0.05, 
ADR day 7 and 14 versus healthy group) at day 7 and 14. 
4.3.4. The CXCL12 blockade has a dual role on the outcome of Adriamycin nephropathy 
To investigate the role of CXCL12 during AN, Balb/c mice were treated with the CXCL12 
inhibitor NOX-A12 or control revNOX-A12 for up to 14 days. As demonstrated in Figure 25A, the 
blockade of CXCL12 had a differential effect on the UACR during AN on day 7 compared to day 14. 
While the UACR was significantly increased following NOX-A12 treatment on day 7, it decreased 
after 14 days in comparison to the control revNOX-A12 group (Figure 26A). Furthermore, the BUN 
levels (Figure 26B), as well as the blood creatinine (Figure 26C), decreased upon treatment with 
NOX-A12 compared to control revNOX-A12 only on day 14. The data suggests that CXCL12 blockade 
had only a protective effect during the late phase of AN but not during the early phase.  
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Figure 26. CXCL12 blockade has a dual effect during Adriamycin nephropathy. Balb/c mice received an 
intravenous injection of ADR to induces AN (see methods 2.2). Two groups of mice received subcutaneous 
injections of either the CXCL12 inhibitor NOX-A12 or control revNOX-A12 thrice a week. Urine was collected on 
day 0, 7 and 14 and the disease markes : UACR (A), BUN (B) blood creatinine (C) were measured. Data are 
mean ± SEM from 6-7 animals per group, *p<0.05 revNOX-A12 versus NOX-A12 at day 7 and 14. 
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4.3.5. CXCL12 blockade and renal morphology on Adriamycin Nephropathy 
To assess morphological changes in the kidney after CXCL12 blockade during AN, whiten the 
group, we stained the kidney sections for PAS and the level of lesions in the NOX-A12 group vs. the 
revNOX-A12 group was evaluated. Quantification of glomerular lesions in the NOX-A12-treated AN 
mice after 7 days showed no difference in the percentage of normal glomeruli (50%), segmental 
lesions (40%) and global lesions (10%) compared to the control revNOX-A12 group (Figure 27A and 
B). Although the function of the kidney decreased following CXCL12 blockade after 7 days (Figure 
27A), there was no worsening in regards of histological changes between the NOX-A12 and revNOX-
A12 group. However, 14 days after AN, the percentage of global lesions increased dramatically 
(75%), whereas the percentage of normal and segmental glomeruli decreased compared to the early 
time point. Interestingly, the blockade of CXCL12 with NOX-A12 resulted in a significant decrease in 
the percentage of global lesions (40%) but in an increase in the percentage of global and normal 
glomeruli compared to revNOX-A12-treated mice (Figure 27B) indicating that CXCL12 blockade 
improved the kidney function during AN. Next, I counted the percentage of crescent formations in 
the glomeruli during AN. As shown in Figure 27C, the percentage of crescents increased during AN 
injected with revNOX-A12 over time (black bars). As expected, the amount of crescent formation 
significantly decreased when CXCL12 was blocked during AN (gray bars). The data demonstrated a 
pathological improvement associated with reduced crescent formation of the kidney following NOX-
A12 treatment during AN. 
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Figure 27: Renal pathology evaluation in Balb/cmice with Adriamycin nephropathy after CXCL12 blockade. 
(A) PAS staining of kidney sections of AN mice in the presence of NOX-A12 or control revNOX-A12 on day 7 and 
14. (B, C) Quantification of glomerular injury score showed that CXCL12 blockade significantly reduced 
segmental and global glomerular lesions (B) as well as glomerular crescents (C) at day 14 during AN. The data 
are means ± SEM from 6-7 animals per group. (*p<0.05 revNOX-A12 group versus NOX-A12 at day 7 and 14), 
(#p<0.05 treated mice at day 7 versus day 14). Original magnification 400x. 
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4.3.6. Podocyte counts after CXCL12 blockade during Adriamycin nephropathy 
Previous in-vitro experiments have shown that CXCL12 can act as a survival factor for 
podocytes. During the characterization of AN mouse model, we showed that the number of 
podocytes in the glomerulus was reduced after ADR treatment. We further evaluated the number of 
podocytes after  CXCL12 blockade during AN. CXCL12 inhibitor had a differential effect on the 
function of the kidney on day 7 compared to day 14 (Figure 28A).  We stained kidney sections with 
an IF for nephrin (green) and WT-1 (red), the staining showed differents in the podocyte counts 
when the mice were treated with NOX-A12 or revNOX-A12 during AN (Figure 28A). Interestingly, 
following CXCL12 blockade, the number of podocytes significantly decreased on day 7compared with 
the control whereas increased after 14 days of AN (Figure 28B). This data is in line with the 
differential effect of CXCL12 on the kidney function: UACR, BUN, and creatinine during AN.  
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Figure 28.  CXC-12 blockade reduces podocyte number in the early phase but increased them in the late. 
Podocytes quantification in wt Balb/cAncrl mice with AN after CXCL12 blockade. While using semi-quantitative 
IF staining for podocytes positive for nephrin (green) and WT-1 (red) (A), we were able to show that CXCL12 
blockade significantly reduced the number of podocytes at day 7 but increased them at day 14 during AN (B). 
The data are means ± SEM from 6-7 animals in each group. (*p<0.05, **p<0.01 NOX-A12 treatment versus 
revNOX-A12 at day 7 and 14 after AN), (original magnification 400x). 
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4.3.7. Renal mRNA expression levels of podocyte markers in total kidney of Adriamycin 
nephropathy with CXCL12 blockade 
To confirm the increased number of podocytes during AN treatment with NOX-A12 and 
revNOX-A12 after 14 days, I evaluated the mRNA expression levels for the classical podocyte 
markers. RT-PCR analysis showed no difference in the mRNA expression levels of the podocyte 
marker nephrin and WT-1 in the NOX-A12 as well as revNOX-A12 treated mice on day 7 (data not 
shown). In contrast, the mRNA levels of Nephrin and WT-1 following NOX-A12 treatment were 
increased in comparison to the control group on day 14 (Figure 29). These data indicating that 
CXCL12 blockade has a general benefit for podocytes on AN day 14.  
 
 
 
 
 
 
 
 
 
 
Figure 29: mRNA expression levels from the kidney Balb/c mice following CXCL12 blockade during 
Adriamycin nephropaty. mRNA was isolated from kidneys of AN mice on day 14 and quantitative real-time 
PCR for the podocyte markers: Nephrin and WT-1  was carried out. The mRNA expression levels were 
significantly increased after CXCL12 blockade compares with control revNOX-A12 during AN. The data are 
means ± SEM from 6-7 animals in each group.(*p<0.05 NOX-A12 treated group versus revNOX-A12 group) at 
day 14. 
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4.4.The role of CXCL12 in human renal progenitor cells and human podocytes in-vitro 
Previously, Darisipudi et al. showed that the blockade of CXCL12 in diabetic glomerulosclerosis 
ameliorates diabetic outcomes including slowing down the onset of proteinuria and increasing the 
number of podocytes. Furthermore, Sargrinati et al. and Ronconi et al. (28, 44) identified a specific 
stem cell population within the human glomerular urinary pole that is positive for both stem cell 
markers CD133 and CD24. Following glomerular damage, this stem cell population can become 
activated and migrate to the glomerular vascular pole into the Bowman´s capsule, and differentiate 
into de-novo podocytes. This raised the question of whether the increased number of podocytes was 
a direct consequence of RPCs regeneration due to the blockade of CXCL12 as demonstrated in the 
study by Darisipudi et al.? In the following section, several experiments were performed to study the 
effect of CXCL12 on RPCs, in particular on their proliferation and differentiation capacity toward 
podocytes in-vitro.  
4.4.1. CXCL12 reduces human renal progenitor cell proliferation capability in-vitro 
Recently, Mazzinghi et al. (88) showed that RPCs express the chemokine receptors for CXCL12 
better known as CXCR-4 and CXCR-7. In this study, the authors demonstrated that CXCL12 is 
necessary for maintaining RPCs quiescence under homeostatic condition. CXCL12 is mainly produced 
by podocytes during homeostasis as well as during inflammatory conditions. Podocytes, as well as 
the RPCs, express the CXCL12 receptors CXCR-4 and CXCR-7 (Table 1). To investigate the effect of 
CXCL12 on RPCs, RPCs were stimulated with culture medium containing 20% FBS in the presence of 
NOX-A12 or control revNOX-A12. FBS was used as a strong pro-proliferation stimulus for RPCs. I 
determined the proliferative capacity and cell viability of RPCs using the colorimetric MTT assay. As 
shown in Figure 30A, stimulation with 20% FBS-induced proliferation of RPCs indicated by a 
significant increase in the optical density (O.D.) value (very light gray bar) that was reduced when 
RPCs were co-incubated with CXCL12 (blue bar). This suppressive effect of CXCL12 on the 
proliferation of RPCs was restored following pre-incubation with the NOX-A12 inhibitor (green bar). 
revNOX-A12 served as a control showing the specificity of NOX-A12 (yellow bar). To mimic the 
physiological condition in the human glomerulus, I differentiated RPCs into podocytes and after 24 
hours the supernatants containing podocyte-derived CXCL12 (PDCXCL12) were collected (Figure 
30B). I cultured then, RPCs in the absence or presence of podocyte-derived CXCL-12. The data in 
Figure 32C showed that 20% FBS-induced the proliferation of RPCs that was significantly reduced 
when podocyte-derived was present in the culture (blue bar) indicating that podocytes are major 
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source of CXCL12 in the glomerulus and that secreted CXCL12 reduced the capability of RPCs to 
proliferate (Figure 30C). 
A                       B 
 
 
 
  
 
 
 
 
C 
 
 
 
 
 
 
 
 
Figure 30: Podocyte-derived CXCL12 reduces human renal progenitor cell proliferation capability. (A) I used 
MTT assay to measure the capacity of human RPCs to proliferate in the presence of the stimulus FBS (20%) or 
in combination with CXCL12. Human RPCs were also co-incubated with the NOX-A12 inhibitor or revNOX-A12 
for 24 hours. The stimulated human RPCs proliferated less when CXCL12 (blue bar) was added. NOX-A12 
(yellow bar) inhibitor partially restored the proliferation capability compared to the control (green bar). (B) The 
experimental layout of the in-vitro experiment. (C) RPCs were cultured with 20% FBS in the absence or 
presence of podocyte-derived CXCL12 for 24 hours. Podocyte-derived CXCL12PODOCYTE DERIVED CXCL12 
significantly reduced the proliferation capability of RPCs.  (****p<0.0001 human RPCs treated with control 
medium versus 20% FBS medium), (§p<0.0001 RPCs treated with 20% FBS versus 20% FBS medium plus 
CXCL12) (§§p<0.001 RPCs treated with 20% medium  versus 20% medium plus CXCL12 and revNOX-
A12),(*#*p<0.01 RPCs treated with 20% FBS plus CXCL12 and revNOX-A12 versus 20% FBS plus CXCL12 and 
NOX-A12), (#p<0.0001 control medium versus 20% FBS medium), (**p<0.01 enriched 20% medium versus 
enriched medium plus podocyte-derived CXCL12), (n.s not significant) after 24h. 
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4.4.2. Necrotic supernatants from lysed podocytes imply human renal progenitors cell 
proliferation via Notch signaling in-vitro 
            During glomerular disease, loss of podocytes is one of the most important features 
responsible for the progression of the injury process. Previously, podocyte derived CXCL12 has 
caused the reduction of RPCs activity. To investigate whether soluble factors from dying podocytes 
can affect RPCs proliferation, I designed an in-vitro experiment, where RPCs were first differentiated 
into podocytes. After obtaining a sufficient number of podocytes, necrotic supernatants were 
prepared as described in section 2.11 and illustrated in Figure 31A. Podocyte-derived necrotic 
supernatants (NS) were added in three different concentrations (1, 10 and 100µl/ml) to RPCs and I 
determined the proliferative capacity by MTT assay after 24 hours. As demonstrated in Figure 31B, 
RPCs proliferate best when 10µl/ml NS is added to the culture. For all further experiments., I used 
10µl/ml of NS for all the  
A  
 
B 
 
Figure 31. Proliferative capacity of renal progenitor cells in the presence of necrotic supernatants obtained 
from podocytes. (A) Podocyte NS was obtained like shown in the cartoon. (B) RPCs were stimulated with 
varying concentrations of NS (1, 10 and 100μl/ml) and 20% FBS (control medium) and cell proliferation was 
quantified using MTT assay after 24 hours. Data are means ± SEM of 2-3 experiments (* p<0.05 human RPCs 
treated with control medium versus RPCs treated with NS after 24h) 
medium 20%FBS 1µl/ml NS 10µl/ml NS 100µl/ml NS
0.0
0.2
0.4
0.6
*
M
T
T
 A
s
s
a
y
 (
O
D
5
7
0
n
m
)
Results                                                                                                                                    
 
62 
 
Next, fresh RPCs were cultured with 10µl NS in the presence of the CXCL12 inhibitor NOX-
A12 and control revNOX-A12 for 24 hours. The MTT assay results showed that blocking CXCL12 in 
the NS increased significantly the capability of RPCs to proliferate (yellow bar) compared to the 
controls NS (red bar) or NS+revNOX-A12 (blue bar) (Figure 32). These results indicated that CXCL12 
was present in the NS and that CXCL12 inhibition increased the NS-induced proliferation of RPCs. It is 
currently unknown how exactly CXCL12 in the NS suppresses RPCs proliferation. To investigate this,  I 
co-incubated RPCs with NS in the absence or presence of the Notch pathway inhibitor DAPT and/or 
NOX-A12.  
 
 
 
 
 
 
 
 
 
Figure 32. Necrotic supernatant induces renal progenitor cell proliferation via Notch pathway. MTT assay 
was carried out and O.D. measured at 570 nm. NS-induced RPCs proliferation (red bar), the inhibition of NS-
CXCL12 with NOX-A12 (yellow bar) increased much more the RPCs proliferation compare with the NS (red bar) 
and NS+revNOX-A12 (blue bar). Further, Incubation with DAPT the inhibitor of the Notch signaling pathway 
drastically reduced the RPCs proliferation capability (black bar). Inhibition of CXCL12 with NOXA-12 or revNOX-
A12 had no effect in the presence of DAPT had no supplementary effects. Data are means ± SEM of 2-3 
experiments. (****p<0.0001 RPCs treated with control medium versus RPCs treated with 20% FBS), (**p<0.01 
treated RPCs with control medium versus NS treated RPCs), (***p<0.001 treated RPCs with 20% FBS versus NS 
treated RPCs), (n.s. not significant), (*p<0.05 treated RPCs with NS plus revNOX-A12 versus RPCs treated with 
NS+NOX-A12), (§p<0.01 treated RPCs with NS plus revNOX-A12 versus RPCs treated NS plus NS plus revNOX-
A12 and DAPT), (#(**p<0.01 treated RPCs with NS plus NOX-A12 versus RPCs treated with NS and NOX-A12 
plus DAPT) at 24h. 
Upon blockade of the Notch pro-proliferative pathway using DAPT the capacity of RPCs to 
proliferative was reduced, whereas stimulation with DAPT in combination with NOX-A12 had no 
further effect on RPCs proliferation (black bars). 
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4.4.3. The role of necrotic supernatant-podocyte-derived CXCL12 and the Notch pathway 
on renal progenitor cells 
The RPCs increased proliferation upon blockade of CXCL12 could be reversed leading to 
increased activity of the Notch signaling pathway during AN. Lasagni et al, (64) have previously 
shown that the activation of the Notch signaling pathway in podocytes can act as a trigger for cell 
death as well as for prolonged Notch pathway activation during AN, increased RPC proliferation and 
differentiation toward podocyte lineage. In the next paragraphs, we investigated the impact of 
CXCL12 on RPCs and the cross-regulation between Notch pathway and CXCL12. To test this 
connection, I stimulated RPCs with 10μl/ml NS and I evaluated the  mRNA expression levels of the 
receptors Notch-1, Notch-2 and Notch-3, the ligands and the downstream genes Hey-1 and Hes-1 of 
the Notch pathway. Real-time qPCR showed that the mRNA levels of all tested genes were 
significantly increased significantly increased following NOX-A12 treatment compared to revNOX-
A12 indicating that NS-derived CXCL12 inhibited Notch signaling activity and, therefore, proliferation 
of RPCs (Figure 33). 
 
 
 
 
 
 
 
 
 
Figure 33: Notch pathway is overactivated when CXCL12 is removed from the prodocyte-derived necrotic 
supernatant. mRNA was isolated from RPCs after NS treatment. The graph showed an increased expression of 
the receptors Notch-1, Notch-2 and Notch-3, the ligands and downstream effector genes Hey-1 and Hes-1 of 
Notch pathway mRNA in RPCs stimulated with NS when CXCL12 was blocked. Data are means ± SEM of 2-3 
experiments, * p<0.05 RPCs treated with NS plus reNOX-A12 versus RPCs treated with NS plus NOX-A12), ( # 
p<0.01 RPCs treated with NS plus NOX-A12 versus RPCs treated with NS plus an extrinsic  surplus of CXCL12) at 
24h. 
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To confirm the mRNA expression levels, I performed a western blot analysis to evaluate the 
expression of the most activated nuclear domain of the Notch receptor 3(NICD-3). The data shows 
an increase in the protein levels of NICD-3 in NS-stimulated human RPCs when CXCL12 was blocked 
compared to the controls (Figure 34). 
 
Figure 34. CXCL12 blockade increases the level of activated the Notch intracellular domain-3. Western Blot of 
RPCs stimulated with NS showed Notch NICD-3 activation after CXCL12 blockade. Data are representative 2-3 
experiments. Protein loading was corrected for sample protein concentrations and Beta-actin was used as a 
control. 
In conclusion, within this section I show that: 1) CXCL12 is present in podocyte necrotic 
supernatants; that 2) Notch signaling is important for RPC proliferation and that 3) CXCL12 can act as 
a direct regulator of the Notch signaling pathway. 
Previously, I showed that CXCL12 released from dying podocytes reduced the activity of 
RPCs via inhibiting the Notch signaling pathway. Next, to confirm the role of CXCL12, I cultured RPCs 
without NS but in the presence of the Notch inhibitor DAPT, CXCL12 as well as the proliferative 
stimulus FBS. The MTT assay performed revealed that 20% FBS-induced the proliferation of RPCs 
(Figure 35, light gray bar) and that upon addition of DAPT (black bar) or CXCL12 (dark gray bar) the 
proliferative capacity of RPCs was significantly reduced compared to FBS alone. However, inhibiting 
proliferation of RPCs with CXCL12 was less effective as DAPT treatment alone and the combination 
treatment of DAPT and CXCL12 had no further effect on RPCs proliferation (squared bar).  
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Figure 35: CXCL12 decreases progenitor cells activation by blocking Notch pathway. RPCs stimulated with 
20% FBS increased their proliferation capability (light gray). The proliferation was significantly reduced in the 
presence of Notch inhibitor DAPT in the medium. Also, the stimulation of the RPCs with CXCL12 reduced again 
the proliferation (gray bar). The combined stimulation with DAPT and CXCL12 no further decreased the RPCs 
proliferation as DAPT performed alone (square bar). Data are means ± SEM of 2-3 experiments (# p<0.0001 
RPCs treated with control medium versus 20% FBS treated RPCs), (****p<0.0001 RPCs treated with 20% FBS 
versus RPCs treated with 20% plus DAPT), (***p<0.001 RPCs treated with 20% FBS versus RPCs treated 20% 
FBS plus CXCL12) (§p<0.0001 RPCs treated with 20% FBS versus RPCs treated with 20% FBS plus combination 
of DAPT and CXCL-12), (*# p<0.01 RPC treated with 20% FBS plus DAPT versus RPCs treated with 20% FBS plus 
CXCL-12), (**p<0.01 RPCs treated with 20% FBS plus CXCL-12 versus RPCs treated with 20% FBS plus 
combination of CXCL-12+DAPT) after 24h. 
Together, the in-vitro data within this section suggest that podocytes are the main source of 
CXCL12 and that podocyte-derived CXCL12has a suppressive effect on RPCs proliferation. Also, 
CXCL12 shows cross-linked effects with the Notch pathway. 
4.4.4. Effects of CXCL12 on human renal progenitor cells differentiation towards podocyte 
lineage  
Previously, Darisipudi, et al. (82) showed that in a mouse model of diabetic nephropathy, 
CXCL12 blockade resulted in an increase in the number of Nephrin/WT-1 double positive cells (82). 
Previously, I showed that podocyte-derived CXCL12 had the ability to act as a homeostatic 
chemokine by reducing the proliferative capacity of RPCs. Less RPCs proliferation can result in less 
de-novo podocyte production. To investigate the direct CXCL12 impact on the podocyte 
differentiation process, I cultured RPCs into podocytes in the presence of VRAD medium for 48 hours 
(28). After stimulation, I determined the expression of different podocyte markers using real-time 
PCR. As shown in Figure 36, the mRNA expression levels of the typical podocyte markers including 
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Nephrin, Podocalyxin, and CD2AP significantly increased after stimulation with VRAD medium 
compared to control medium (green bar). However, when human RPCs were stimulated with CXCL12 
during the differentiation process, the mRNA levels of all three tested podocyte markers decreased. 
This suppressive effect of CXCL12 on Nephrin, Podocalyxin and CD2AP mRNA expression was 
partially rescued by blocking CXCL12 with the NOX-A12 antibody in comparison to the control 
revNOX-A12 antibody. This results show that CXCL12 reduce the capability of RPCs to differentiate 
into podocyte. 
 
 
 
 
 
 
Figure 36. CXCL12 reduces renal progenitor cell differentiation towards podocyte lineage. (A) RPCs were 
differentiated without (EBM control media) or with VRAD medium (see methods 2.11) into podocytes and then 
treated with CXCL12 alone or in combination with NOX-A12 or revNOX-A12 for 48 hours. qPCR analysis was 
performed on human RPCs looking at the mRNA expression levels of Nephrin, Podocalyxin, and CD2AP. Data 
are means ± SEM of the 2-3 experiment. (* p<0.05, *** p<0.001 RPCs stimulated with control medium versus 
RPCs stimulated with VRAD medium), (#p<0.05 RPCs stimulated with VRAD plus CXCL12 and NOX-A12 versus 
RPCs treated with VRAD medium plus CXCL12 and revNOX-A-12. 
 
4.4.5. Blocking CXCL12 increases renal mRNA expression levels of Notch pathway genes 
during Adriamycin nephropathy  
Previous in-vitro studies showed that stimulation with NS was able to reduce the proliferative 
capability of RPCs, associated with a negative regulation of the Notch signaling pathway by CXCL12. 
To investigate if CXCL12 can also trigger a reduction of Notch expression levels in-vivo, I performed a 
qPCR expression analysis on total kidney mRNA from mice following AN, treated with /without 
CXCL12 inhibitor. As shown in Figure 37, the mRNA expression levels of the Notch receptors Notch-1, 
Notch-2 and Notch-3 increased during AN, day 7 and 14, when CXCL12 was blocked using the NOX-
A12 inhibitor compared with the control. (Figure 37A, black bars). Similar to the Notch receptor 
mRNA profile, the mRNA expression levels of the Notch ligands Jag-1, Jag-2 and Dll-1 (Figure 37B) as 
well as the downstream effectors genes Hes-1 and Hey-1 (Figure 37C) were significantly up-regulated 
following treatment with NOX-A12 compared to control revNOX-A12 on day 7 and 14. 
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Figure 37. Upregulation of Notch-related genes following CXCL12 blockade during Adriamycin nephropathy. 
mRNA was isolated from kidneys of AN mice following CXCL12 blockade and showed an increased expression 
of the receptors Notch-1, Notch-2 and Notch-3 (A), the ligands Jag-1, Jag-2 and Dll-1 (B) and the downstream 
effectors genes Hes-1 and Hey-1 (C) of the Notch pathway in kidneys on day 7 and 14. Data are ± SEM from 6-7 
animals in each group. (*p<0.05, **p<0.01 ADR treated mice with NOX-A12 versus mice treated with ADR and 
revNOX-A12) at day 7 and 14. 
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4.4.6. The Notch pathway intracellular domains are highly expressed in the injured 
glomerulus following CXCL12 blockade Adriamycin nephropathy 
To confirm that CXCL12 was responsible for the inhibition of Notch signaling activity during 
AN, We stained kidney sections from mice treated with NOX-A12 or revNOX-A12 during AN on day 7 
and 14 for the Notch intracellular domain 1 (NICD-1) and NICD-3. As showed in Figure 38A, the 
expression of NICD-3 (green) in the kidneys of AN was increased compared to healthy mice on day 7 
(Figure 38A upper panel), in contrast, the expression of NICD-3 decreased on day 14. The fluorescent 
intensity of NICD-3 was stronger in kidney sections of mice treated with NOX-A12 compared to 
control revNOX-A12 during AN on day 7 and 14 (Figure 38A, lower panel). Especially on day 7, NICD-
3 was highly expressed inside the podocyte cytosol and in the parietal epithelial cells, compared to 
the revNOX-A12 (Figure 38A lower panel). Lasagni, et al. (64) showed that NICD-3 activation in 
podocyte was a triggering signal to go under proliferation program. This program occurs due to the 
podocyte structural characteristics cannot be done. When the cell cycle of podocytes is abolished, 
they died via CM.  (Here, in this thesis were presented only in-vitro direct experiment about ADR-
induced CM and its regulation. At the moment the direct prove of this mechanism Notch pathway-
CM and CXCL12 in-vivo are under evaluation with animal experiments (64). Together with the 
previous mRNA data and these IF sections, I confirmed that podocyte’s derived CXCL12 had a 
homeostatic-down regulation of Notch role, on the RPCs but also on the podocytes. Continuing on 
the work of Lasagni, et al. (64), we also checked the NICD-3 signal at the day 14 during the 
regeneration phase of AN. NICD-3 was much stronger inside the PECs (activated RPCs) during the 
regeneration phase of the model (Figure 38A low pictures). Indeed, on day 14 mice treated with 
NOX-A12 represent a stronger NICD-3 signal in PECs compared to revNOX-A12 indicating that the 
proliferation of PECs via Notch pathway was a consequence of more de-novo podocyte regeneration. 
In addition, this staining showed that CXCL12 had a suppressive effect on the activity of NICD-3 
during AN. This was also the case for NICD-1 on day 14 (Figure 38B).  
 
 
 
 
 
  
Results                                                                                                                                    
 
69 
 
A 
 
B 
 
Figure 38. CXCL12 down-regulates Notch 1-3 signaling activity in Adriamycin nephropathy.  (A) 
Representative images of kidney sections stained for the activated Notch-domain NICD-3 demonstrated that 
CXCL12 blockade increased the positivity for NICD-3 on day 7 and 14 compared with the control or healthy 
status. (B) Representative images of kidney sections stained for activated Notch-domain NICD-1 on day 14; 
here the PECs were positive when treated with NOX-A12 compare to revNOX-A12. Original magnification is 
200x. 
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Together, the in-vitro and in-vivo findings indicate that CXCL12 could act as a survival factor 
for podocytes in an autocrine manner. In particular, CXCL12 released from dying podocytes is able to 
down-regulate the expression of Notch signaling in podocytes. CXCL12 is also necessary during the 
early phase of AN to keep the podocytes alive and to block Notch pathway activation and preventing 
other podocytes to die via CM. In contrast, during the late phase (day 14) of AN, blocking CXCL12 is 
beneficial for the activation and further differentiation of RPCs to de-novo podocytes resulting in the 
amelioration of the disease. 
4.5.Blockade of CXCL12 during Adriamycin nephropathy using a mouse renal progenitor 
cell-lineage tracing-system 
Are de-novo podocytes derived from RPCs within the glomerular stem cell niche or from other 
stem cell sources? Does glomerular regeneration via RPCs de-novo podocyte formation occur during 
AN in-vivo? To further confirm our findings in the AN model, I used a novel technic based on the 
lineage-tracing-system. Therefore, we obtained a specific mouse strain, tagged with the tracing 
endogenous red florescent protein /endogenous green florescent protein (ERFG/EGFP) system for 
the Pax2 promoter (Pax2 mT/mG) from our collaborators in Florence. Pax2 is a critical regulator of 
the embryonic progenitor population during kidney development in vertebrates (137). Pax2 is co-
expressed with CD133 in the adult RPCs, and it was an ideal combination for RPCs lineage tracing 
along the Bowman´s capsule of the mouse (138). I induced FSGS after activation of the mT/mG 
tracing system like described in section 2.2. Consequently, I started CXCL12 blockade treatment from 
time point day 0 until the end of the experiment on day 33. After that, we used a confocal IF to 
visualize the endogenous mouse Pax2 reporter and specific podocyte markers to evaluated the 
impact of mouse RPCs on the podocyte regeneration after AN. 
4.5.1. The effect of blocking CXCL12 during Adriamycin nephropathy 
I determined the UACR in the  Pax2.rtTA; TetO.Cre; mT/mG mice during the treatment with 
the active or inactive CXCL12. CXCL12 inhibition significantly reduced UACR (Figure 39A). Also, the 
BUN levels were decreased although not significantly upon treatment with NOX-A12 compared to 
control revNOX-A12 (Figure 39B). The data suggested that CXCL12 blockade had also a protective 
effect during the regeneration phase of AN in Pax2 mice.  
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Figure 39: CXCL12 blockade reduces Adriamycin nephropathy disease marker in Pax2 mice. Adriamycin 
nephropathy was established as described in methods section 2.2 in Pax2 mice. Two groups of mice received 
NOX-A12 and revNOX-A12 as described in methods section 2.2 Urine was collected and the UACR was 
evaluated along all the treatment period(A) and BUN (B) measured at the end of the study. Data are means ± 
SEM from 5 animals group. (*p<0.05 NOX-A12 treated AN mice versus revNOX-A12 group) at day 33. 
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4.5.2. Pax2-tagged mouse renal progenitor cells regenerate lost podocytes during 
Adriamycin nephropathy 
Blocking CXCL12 reduced proteinuria in Pax2 mice with AN. To determine the expression of 
Pax2 in the kidneys, I performed IF with the endogenous green and red fluorescent proteins system 
to identify the de-novo mouse podocytes derived from mouse RPCs (Figure 40A). The endogenous 
red fluorescent protein was used to define the old embryonic Pax2-derived podocytes before the 
activation of mt/mG system in the glomeruli. The green stained for the de-novo podocyte-derived 
from the Pax2 mouse RPCs. Also, we stained with blue color the podocyte marker synaptopodin 
(Syn) and the nuclei with the marker DAPI (white color). As illustrated in Figure 40B (top panel), the 
glomerular sections showed a mix of purple cells representing pre-induced podocytes (red color plus 
Syn in blue and green cells with a blue background as de-novo treatment-induced podocytes. The IF 
staining demonstrated that treatment with the CXCL12 inhibitor NOX-A12 results in more newly 
derived de-novo RPCs (green color) compared to the revNOX-A12 group. Without staining for Syn 
(blue color), the glomerular sections showed that the NOX-A12 group had more Pax2 activated PECs 
(green color) in the capsule compared to the control (Figure 40B, lower panel) at day 33. 
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Figure 40. CXCL12 blockade induces activation of renal progenitor cells Pax2 cells toward de-novo podocytes 
in Adriamycin nephropathy. Pax2 AN was induced as described in methods 2.2. (A) Pax2 mT/mG bgenetic 
schematic model. (B) (upper panel) IF of Pax2 mouse with red/blue staining of pre-induced podocytes, green 
stained cells are in the center of the glomerulus that are de-novo podocytes derived from the Pax2 mouse 
renal progenitor. Green cells around the capsule are activated transitional PECs/ podocytes. (B) (lower panel) 
IF of Pax2 mice without blue Syn staining to better evaluate the foot process of the de-novo podocytes (green 
cells). Representative pictures, original magnification 400x.  
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To further estimate the impact of mouse RPCs in podocytes regeneration, I determined the 
total amount of positive Pax2 cell glomeruli inside one entire kidney longitudinal section under the 
microscope. The resulted data showed a higher Pax2 positivity in the NOX-A12 group,  15% of  the 
total glomeruli were positive, compared with the control treatment were 4.5% of the glomeruli were 
Pax2 positive (Figure 41A left up graph).  Since glomerular damage is focal and segmental in this 
model, it was possible to assume that not all glomeruli containing Pax2+cell-derived podocytes 
within the tuft and that not all Pax2+ cells were present within these glomeruli. To further evaluate 
the activated mouse RPCs, I further counted the total number of absolute n° of Pax2-derived 
podocyte per glomeruli per all the glomeruli of the longitudinal section. Again the results were 
significant as NOX-A12-treated mice showed 3 times more Pax2-derived podocytes in absolute 
counts compared to revNOX-A12 (Figure 41A right up graph). Finally, I estimated the regenerative 
impact of Pax2 cells during AN while using the Podo loss formula of Lasagni et al, (27) (see methods 
2.10). The percentage of Pax2--derived podocytes-Syn+ over lost podocytes was three times higher 
in the NOX-A12 treated group (13%) compared to the revNOX-A12 (2.7%) (Figure 41A low graph). 
Using a high magnification, it was possible to visualize the complex structure of podocytes (green 
color), the podocyte foot process and the integrated new green podocyte inside the glomerular 
contest (cells with red color) (Figure 41B). 
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Figure 41. CXCL12 blockade induces activation of the renal prognitor cell-Pax2 cell toward de-novo 
podocytes in a Adriamycin nephropathy. AN was induced as described in methods 2.2. (A) Evaluation of the 
percentage of glomeruli with Pax2 derived podocytes upon treatment with NOX-A12 or revNOX-A12 (left 
graph), the number of Pax2-derived podocytes per glomerulus of all glomeruli (middle graph), the percentage 
of Pax2-derived podocytes positive for Syn over lost podocytes (right graph). (B) Representatives pictures with 
high magnification of Pax2-derived podocyte following NOX-A12 treatment on day 33. In panel B-left podocyte 
with Syn-co-staining, B-right panel, only endogenous IF colors. Data are means of ± SEM from 5 animals per 
group (*p<0.05 NOX-A12 treated AN mice versus revNOX-A12) group at day 33. Representative pictures, 
original magnification 600x.  
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Together, We show that blocking CXCL12 during AN  can unblock the mouse RPCs from the 
CXCL12-induced quiescence, boosting the podocyte regeneration and ameliorates ANdisease 
markers and  glomerular injury. 
4.6.Therapeutic blockade of CXCL12 during Adriamycin nephropathy 
This conclusive section investigated the possible use of CXCL12 blockade in the established 
disease contest. Here, I induced AN (see section methods 2.2) where the anti-CXCL12 treatment 
started one week after the disease induction. To investigate whether blocking CXCL12 
therapeutically would be beneficial for the regeneration of RPCs during AN, mice were treated with 
NOX-A12 one week after the induction of AN till the end of the study. As shown in Figure 42A, the 
UACR ratio was significantly reduced upon NOX-A12 treatment compared with control revNOX-A12. 
Besides the UACR, the BUN level also has a decreased trend following NOX-A12 treatment (Figure 
42B).  
A                 B 
 
 
 
 
 
 
 
Figure 42. Effects of the CXCL12 blockade during the late phase of Adriamycin nephropathy. Mice were 
treated as described in methods section 2.2 to induce AN.  Therapeutic CXCL12 blockade from day 7 protected 
the kidney during AN compared to the control group as shown by UACR (A). BUN also showed a positive trend 
when CXCL12 was blocked (B). The data are means ± SEM from 6-7 animals in each group. (*p<0.05 NOX-A12 
treated AN mice versus revNOX-A12) at day 14. 
Next, I evaluated the glomerular injury from kidney sections of NOX-A12 treated mice 
(Figure 43A). The data demonstrated that blocking CXCL12 with the NOX-A12 resulted in a significant 
increase in the number of normal and segmental lesions per glomeruli, whereas the number of 
global glomerular lesions decreased compared to the control revNOX-A12 group (Figure 43B). 
Furthermore, I assessed the percentage of crescent formations during AN, I found that inhibiting 
CXCL12 decreased the number of crescents in the kidney on day 14 (Figure 43C). 
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Figure 43. Therapeutic inhibition of CXCL12 decreased global lesions and crescents during Adriamycin 
nephropathy. Two Balb/c mouse groups of mice received subcutaneous injections of the CXCL12 inhibitor 
NOX-A12 or control revNOX-A12 from day 7 until day 14 after induction of AN (see,ethods section 2.2). (A) PAS 
staining showed that therapeutic CXCL12 blockade significantly reduced global glomerular lesions (B) as well as 
glomerular crescents on day 14 during AN (C). The data are means ± SEM from 6-7 animals per group. 
(*p<0.05, **p<0.01 NOX-A12 treated AN mice versus revNOX-A12) at day 14. Representative pictures, original 
magnification 400x.  
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4.6.1. Therapeutic blockade of CXCL12 in Adriamycin nephropathy increases podocyte 
numbers at the end of the treatment 
After assessing the typical disease markers and morphological changes of the kidney, I 
evaluated the effect on podocytes using IF for nephrin and WT-1. As shown in Figure 44A, the 
number of double positive cells (Nephrin/WT-1) increased in the NOX-A12-treated mice compared 
to the control group, which was quantitatively confirmed by counting the number of podocytes per 
glomeruli (Figure 44B). 
A          B 
 
Figure 44. Podocyte counts increased in the kidney of therapeutic CXCL12 blockade Adriamycin 
nephropathy. Two Balb/c groups of mice received subcutaneous injections of the CXCL12 inhibitor NOX-A12 or 
revNOX-A12 from day 7 until day 14 after one week of established AN (see methods section 2.2). (A) 
Representative images of kidney glomerulus stained for the podocyte markers nephrin (green) and WT-1 (red). 
(B) Therapeutic CXCL12 blockade significantly increased the number of podocytes on day 14 after one week of 
treatment. The data are means of ± SEM from 6-7 animals per group. (*p<0.05 NOX-A12 treated AN mice 
versus revNOX-A12 mice). Original magnification 400x. 
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4.6.2. Notch pathway is activated in therapeutic blockade of CXCL12 
Next, we stained kidney sections from mice treated with or without the CXCL12 inhibitor on 
day 14 for the activated domain NICD-3 (Figure 45). The fluorescence intensity of the NICD-3-
activated domain was up-regulated inside the PECs when CXCL12 was blocked at day 14 compared 
to revNOX-A12. This indicates that CXCL12 was down-regulating the Notch signalling activity during 
established AN. 
 
Figure 45. CXCL12 down-regulates Notch signaling activity in established Adriamycin nephropathy. 
Representative images of kidney sections stained for activated Notch-domain NICD-3 demonstrated that 
CXCL12 blockade increased the expression of Notch-3 in established AN compared to the control group. 
Original magnification is 400x. 
In conclusion, the data demonstrate that therapeutic CXCL12 blockade was beneficial for a 
better outcome of established AN, in particular due to the glomerular induced Notch-RPCs-podocyte 
regeneration. This highlights the therapeutic potential of blocking CXCL12 during an establish FSGS. 
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5. Discussion 
Glomerulonephritis represents an important kidney disease entity, however, little is known 
about the biological effects of the chemokine CXCL12 in glomerular homeostasis and disease, e.g. in 
AN. Studies have been performed to explore the role of CXCL12 in diabetic nephropathy (82, 83), 
however never in AN. This thesis provides further insights into the pathomechanisms involved in the 
progression during AN, and glomerular regeneration, in particular, the specific effects of CXCL12. 
CXCL12 in the glomerulus is produced by podocytes in healthy and sick status. Darisipudi, et 
al. (82, 83) demonstrated that CXCL12 blockade is beneficial during diabetic nephropathy. However, 
the results of these studies left open questions about the molecular mechanisms of CXCL12. First, 
why do podocytes produce CXCL12 during glomerular homeostasis and injury? Second, how do the 
amelioration effects of CXCL12 blockade happen if the immune compartment is not involved? And 
third, how does CXCL12 blockade increase podocyte counts? 
This thesis addressed the role of CXCL12 using several different research approaches: 
1) Using mouse disease models based on podocyte-depletion and CXCL12 blockade. 
2) Using mouse model based on specific podocyte progenitor lineage tracing. 
3) Using RPCs to study the de-novo origin of podocytes and a possible link between CXCL12, 
podocytes and RPCs. 
Our data now document a dual homeostatic effect on the terminally differentiated 
podocytes as well as on their local podocyte progenitor cells during homeostasis, injury, and repair. 
First, the constitutive expression of CXCL12 has an autocrine survival effect on podocytes, which 
helps them to withstand stress or injury. Second, CXCL12 expression promotes the quiescence of 
local podocyte progenitors, a mechanism that may support homeostasis but that also limits their 
regenerative capacity upon podocyte loss. Thus, while CXCL12 blockade can promote podocyte loss 
during the injury phase, it may enforce podocyte regeneration and improve long-term outcomes 
when administered in the regeneration phase of the glomerular disease. Until now, the functional 
significance of CXCL12 being constitutively released from podocytes is unknown. To test whether 
podocyte-derived CXCL12 can function in an autocrine manner during podocyte injury, human 
podocytes were exposed to ADR in the presence of either the active or inactive CXCL12 inhibitor. 
ADR significantly increased the podocyte cell death ratio. This stimulation was attenuated by 
extrinsic CXCL12 indicating a pro-survival effect of CXCL12 on human podocytes. CXCL12 inhibitor 
abrogated this protective effect of CXCL12. Further, we demonstrated in a specific mouse podocyte 
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depletion system that the blockade of intrinsic CXCL12 significantly aggravated UACR, which was 
associated with a lower number of podocytes. In another AN model, CXCL12 inhibition aggravated 
proteinuria in association with more glomerular injury and lower numbers of podocytes at the early 
time point. The analysis confirmed that CXCL12 inhibition accelerated the loss of preexisting 
podocytes. Thus, intrinsic CXCL12 was a podocyte survival factor and also reduced the ADR-induced 
CM by Notch pathway blockade. We further confirmed that CXCL12 was a homeostatic chemokine 
for mouse and human renal progenitor cells. In-vitro experiments demonstrated that extrinsic 
CXCL12 as well as podocyte-derived CXCL12 blockade increased the capability for the proliferation of 
renal progenitor cells and for their differentiation toward podocyte lineage. Also, we were able to 
show that RPCs proliferation was associated with the upregulation of the Notch pathway and that 
CXCL12 regulated this equilibrium. During a model of AN, CXCL12 blockade regulated the activation 
and proliferation of RPCs along the BC promoting the de-novo differentiation and replacement of 
lost podocytes during regeneration. This regeneration phenomenon was assessed using a lineage 
mouse model that showed de-novo PAX2-derived podocytes over the AN loss of podocytes. Finally, 
we determined using a therapeutic interventional mouse model that the late blockade of CXCL12 in 
established AN was able to promote podocyte regeneration resulting in positive outcomes regarding 
AN disease markers as well as UACR, BUN, and glomerular injury score. We conclude that CXCL12 
inhibition could be a novel therapeutic strategy to promote podocyte regeneration upon injury and 
to prevent progressive glomerulosclerosis, one of the most common causes for end-stage renal 
disease. 
CXCL12 is constitutively expressed by podocytes 
CXCL12 was first described as a growth factor expressed in numerous hematopoietic and 
non-hematopoietic tissues e.g. bone marrow and lungs (72, 139). CXCL12 is known to be an essential 
regulator of progenitor cell homing and recruitment (73, 74), which includes bone marrow 
progenitors of the hematopoietic system as well as committed progenitors in peripheral tissues (75, 
76). However, CXCL12 is also known as a “homeostatic” chemokine and it belongs to a category of 
chemokines that act independently of inflammation (140). In recent years, many studies 
demonstrated that CXCL12 is produced and secreted from podocytes during primitive glomeruli 
development and in healthy mature glomeruli, as shown by Takabatake, at al. when using a genetic 
mT/mG lineage-tracing mouse system (106). Haege, et al. showed with an elegant dual in-situ 
hybridization of 35S labeled probes for CXCL12 and a DIG-labeled probe for the podocyte marker WT-
1, that during capillary tuft development CXCL12/CXCR-4 signaling is necessary between podocytes 
and glomerular capillaries but also its activity in mature podocytes (103). For example Balabian, et 
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al. showed by IF that CXCL12 was produced by podocytes in the glomeruli of NZB/W mice with lupus 
nephritis (116). Further, CXCL12 blockade was performed during a mouse model of type 2 diabetic 
nephropathy, where Sayyed, et al. showed using immunofluorescent staining that CXCL12 was 
produced by podocytes in healthy, early and advanced diabetic nephropathy (83). They further 
demonstrated that CXCL12 blockade reduced glomerulosclerosis, UACR and increased podocyte 
counts (83). In this contest, my work confirmed these previous findings (Figure 46). Using 
immunofluorescent staining for Nephrin and CXCL12 on human-derived podocytes in-vitro, we 
showed that podocytes constitutively express CXCL12. Furthermore, I used immune and 
immunofluorescent staining on mouse kidney section showing that in healthy and glomerular 
disease conditions, podocytes are the major glomerular source of CXCL12 and that in normal mature 
glomeruli, podocytes constitutively express CXCL12 and this continues during AN.  
 
Figure 46. Diagram representing CXCL12 produces by podocytes in the glomerular environment. The 
podocytes are the glomerulus major source of CXCL12. We showed that during health and injury the CXCL12 Iis 
secrete the podocyte is to the glomerular environment. 
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CXCL12 is an autocrine survival factor by preventing Notch-mediated catastrophic mitosis 
Podocytes are terminally differentiated cells that constitute their functional contribution to 
the glomerular filtration barrier via their complex structural interdigitations involving their actin 
cytoskeleton (3). Upon glomerular injury podocytes frequently enter the cell cycle to undergo 
hypertrophy but cell cycle arrest is needed to avoid accidental mitosis as mitosis requires the actin 
cytoskeleton to form the mitotic spindle, a process that is hardly compatible with maintaining the 
foot processes referred to as “mitotic catastrophe” (70). Lasagni, et al. showed with an elegant 
study, that podocytes catastrophic mitosis molecular mechanisms are connected with the Notch 
pathway (64). In particularly, they showed with an NICD-infected podocytes, that a persistent Notch 
pathway activation in podocytes induces the podocytes to cross over the G2/M checkpoint phase of 
the mitosis (64). Furthermore, podocytes undergoing forced nuclear division are unable to execute 
cytokinesis for the downregulation of Aurora kinase B, p21Cip1/WAF-1 and p27Kip1 (64) up which results 
in polyploid podocytes with a cytoskeleton disruptions, podocyte depletion and cell death via 
catastrophic mitosis (Figure 47). Moreover, Lasagni, et al. showed in human biopsies of FSGS and 
lupus nephritis by IF that Notch NICD domain1-2-3 as well as the downstream genes Hey-1 and Hes-1 
were highly expressed in podocytes and RPCs (64). They also demonstrated in SCID mouse model of 
AN, without the interference of T lymphocytes, that 7 days after AN induction UACR increased in 
correlation with an over-expression of NICD-1-3 in podocytes co-stained for WT-1 and that this 
increased expression of NICD-3 correlated with an increased IF staining levels for active H3-Ser10, a 
marker for catastrophic mitosis. Also, electron microscopy at the late time point after 21 days 
showed catastrophic mitosis in podocytes (64). The loss of podocytes was reversible, as well as the 
increased UACR, if the induced AN mice were treated with the Notch pathway inhibitor DAPT. 
Treatment with DAPT until day 7 resulted in reduced IF positivity for H3-Ser10/Nephrin in podocytes 
and decreased levels of NICD-1-3 (64). Recently, Mulay et al. showed in an in-vitro experiment that 
human RPC-derived podocytes are going under catastrophic mitosis when stimulated with ADR. 
However, they reduced the impact of the ADR-induced catastrophic mitosis by blocking the cell cycle 
(136) and showed via IF that podocytes expressed high levels of murine double minute (MDM)-2. 
While using the MDM2 inhibitor nutlin-3a they were able to arrest the ADR-forced podocyte cell 
cycle in the G2/M checkpoint (136). Consequently, the arrest of the cell cycle reduced the podocytes 
in catastrophic mitosis in-vitro visible with negative IF staining for H3-Ser10 and normal alpha tubulin 
staining. Mulay et al. furthermore confirmed the effects on podocytes in-vivo. Treatment of AN with 
nutlin-3a ameliorated UACR, BUN, glomerular score compared to the control, and the podocyte 
count was higher when cell cycle was arrested (136). One further prove was that podocytes crossing 
the M phase of the cell cycle is required for podocytes to undergo catastrophic mitosis. Migliorini, et 
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al.  demonstrated in a SCID AN mouse model treated with interferon-β that podocytes were more 
positive for H3-Ser10 compared to the control (141). In this context of induced podocyte 
catastrophic mitosis, my work introduced the concept that CXCL12 reduces catastrophic mitosis. My 
data provide evidence that podocyte-derived CXCL12 acts in an autocrine survival manner on 
podocytes by reducing Notch pathway activation and inhibiting aberrant podocyte mitosis leading to 
podocyte loss, i.e. mitotic catastrophe. Furthermore, using a Diphtheria toxin nephropathy, in-vivo 
model, CXCL12 blockade reduced podocyte counts and increased mortality of Diphtheria toxic 
treated mice. This was also the case when CXCL12 was blocked during the early time point of AN. 
Thus, CXCL12 is an intrinsic antagonist of Notch signaling and therefore, supports podocyte 
quiescence and homeostasis. In turn, Notch signaling is a known inducer of CXCL12 and CXCR-4 
implying a balance based on a negative feedback loop between signals (142, 143) As a consequence, 
CXCL12 inhibition uncouples Notch signaling and subsequently promotes podocyte loss via mitotic 
catastrophe during acute glomerular injury. Together, we first showed that CXCL12 is an autocrine 
podocyte survival factor via inhibiting Notch-induced catastrophic mitosis. 
 
Figure 47. Diagram representing podocytes-derived CXCL12 during Adriamycin nephropathy and Notch-
induced catastrophic mitosis. (A) During glomerular injury, podocytes produce CXCL12. CXCL12 acts in an 
autocrine manner in podocytes and can block the Notch pathway. Reducing the activation of the Notch 
pathway, podocyte cannot override the G2/M phase and undergo catastrophic mitosis. (B) CXCL12 blockade 
induces the activation of the Notch pathway in podocytes and drives them to catastrophic mitosis, 
apoptosis, and GBM detachment.  
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Podocyte-derived CXCL12 controls local renal progenitor cell quiescence 
In previous studies, CXCL12 has been implicated not only in stem cell adhesion but also in 
the induction of stem cell proliferation/survival (144-146). In addition, CXCL12 was found to be 
critical for the development of several organs suggesting that this chemokine may play a role in the 
migration, adhesion, proliferation and survival of most adult progenitor cells (145). Some groups 
addressed the origin of such novel podocytes and consistently found intrarenal progenitor cells that 
permanently reside within the PECs layer along the Bowman´s capsule, called RPCs (27, 135). 
Sagrinati, et al. isolated a CD24+ CD133+ double positive cell population and characterized this 
population for staminal properties including self-renewal and clonogenic potential. The double 
positive CD24+ CD133+ PECs in comparison with the double negative control CD24- CD133- cells 
were able to proliferate for a long time in culture after isolation from the donor. Like the human 
embryonic kidney cell line (HEK), RPCs overexpressed the transcription factor Oct-4 and Bml-1 
compared to the mature double negative cells (135). Furthermore, they enriched the RPCs 
population and found that RPCs have the capacity to differentiate under appropriate culture 
condition to multi-lineage cell types, e.g. podocytes and tubular cells within the glomerulus or into 
osteogenic and adipocyte extraglomerular cell lineage (46, 135). Within the same group, Mazzinghi, 
et al. did an extensive study looking at the role of CXCL12 on RPCs. They found by IF that adult stem 
cells expressed high levels of the CXCL12 receptors CXCR-4 and 7 using RT-PCR analysis and a 125I-
CXCL12 binding assay (88). As mentioned before, CXCL12 is required for the survival and anti-
apoptotic effect of bone-marrow stem cells and adult stem cells. Mazzinghi, et al. confirmed that 
CXCL12 mediates the survival of RPCs, when CXCL12 is in close interaction with the receptor CXCR-7. 
In our study, we showed that podocytes are the major source of CXCL12 in homeostasis and injury, 
and that CXCL12 is a homeostatic RPC chemokine by reducing the capability of RPCs to proliferate. 
We also indirectly demonstrated using NS and directly using podocyte-derived CXCL12 that during 
the intensive loss of podocytes, there is a CXCL12 secreted from podocytes into Bowman´s space, 
which prevents RPCs activation and proliferation (Figure 48). This mechanism can be described as a 
security feedback loop of podocytes on RPCs to prevent the activation and over-proliferation of 
RPCs. Previous data have shown that CXCL12 expression can be further increased by podocytes 
during glomerulonephritis (116). This deregulation of CXCL12 production seems to be related to the 
development of nephritis (116). The CXCL12/CXCR-4 axis is involved in such excessive epithelial 
hyperplasia, which is presented as crescentic glomerulonephritis (35, 117). Recently, studies 
demonstrated that in diseases with massive loss of podocytes and loss of GBM, e.g. Alport syndrome 
and crescentic glomerulonephritis , committed PECs along the Bowman´s capsue trying to reduce 
crescent formation and FSGS (30, 31, 51). The homeostatic control of the RPCs is still not fully 
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understood (35). The pharmacological use of controlling RPCs is now under evaluation in the context 
of AN (27).  
 
Figure 48. Diagram representing podocyte-derived CXCL12 controls local renal progenitor cell quiescence. 
(A) During glomerular injury, podocyte-derived CXCL12 acts as proliferation suppressor for RPCs, stops RPCs 
from overproliferation and starts to make crescents formations. (B) CXCL12 blockade during glomerular injury 
in the late phase of the disease leads RPCs to proliferate along the BC and RPCs can differentiate into de-novo 
podocytes. 
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Therapeutic CXCL12 blockade can enhance the regeneration of podocyte loss during 
glomerular injury from a local podocyte progenitor source 
The course of CKD can be extremely variable. Commonly CKD originates from the 
glomerulus, where podocytes, the major components of the GBM, are lost or detached in a 
significant quantity with an estimation of more than 40% (26, 147). Certain renal diseases quickly 
lead to irreversible ESRD. In daily clinic practice, unluckily, the evidence for ERSD can be detected by 
UACR, BUN and creatinine, also using kidney biopsies when the disease is already manifested. There 
are no clinical methods available to repair podocyte damage. However, if the injury exceeds a 
certain threshold, podocyte hypertrophy reveals itself to be an unfit strategy over time, as the loss of 
podocytes and segmental sclerosis leads to podocyte detachment and a decreased ultrafiltration 
capacity (29). Since the RPCs were isolated and characterized, many studies had been performed to 
evaluate the regeneration capability of these RPCs in kidney diseases context. Sagrinati, et al. 
showed that during AKI induced by glycerol-rhabdomyolysis, the injection of human RPCs 
ameliorates the disease markers (135). Afterward, Ronconi, et al. showed in an AN model in SCID 
mice that injections of human RPCs ameliorate UACR, BUN and PAS score (28). These data was 
further confirmed by the work of Peti-Peterdi, et al. where they demonstrated by using multi-photon 
microscopy, that RPCs replaced the lost podocytes in a rat model of PAN-nephritis 
(glomerulonephritis, arteriolitis, and tubulointerstitial nephritis) (148). Further on, Angelotti, et al. 
confirmed that RPCs can differentiate into tubular lineage. Also, mice treated with human RPCs that 
were labeled with IF-cell marker, that RPCs were well engrafted in the mouse tubuli after one week 
and that RPCs showed proliferation activity to restore the damaged tubular cells in the injured 
nephrons and this was associated with amelioration on AKI disease markers (46). Later on, Peired, et 
al. unravel the mechanisms of RPCs activation and podocyte regeneration in AN. They investigated 
the impact of UACR on the regeneration of podocytes during AN, and found that RPCs differentiate 
into podocyte when retinol present in the urine was converted into retinoic acid in the Bowman´s 
space by the PECs RARE enzyme to become podocytes. When UACR is present in high levels, the lack 
of albumin in the Bowman´s space is binding the retinol and blocking the differentiation of RPCs into 
podocytes, which leads activated PECs to make crescent formations (56). Wanner, et al. data 
revealed that podocyte generation is mainly confined to glomerular development and may occur 
after acute glomerular injury, but this does not relate to podocytes in aging kidneys or in response to 
nephron loss (132). Lasagni, et al. partially unraveled the role of the Notch pathway during AN. They 
showed that different phases of AN require differential activation of the Notch pathway. Notch 
pathway activation during the injury phase of AN induces podocyte catastrophic mitosis and 
consequently aggravation of the AN. During the recovery phase of AN activation of the Notch 
Discussion                                                                                                                              84 
 
84 
 
pathway leads to RPCs proliferation and differentiation into podocyte lineage followed by an 
amelioration of UACR and other disease markers (64). The inhibition of Notch via pharmaceutical 
modulation with DAPT was one of the first studies were the authors tried to modulate the behavior 
of RPCs during AN (64). In a follow-up study, the outcome of AN was modulated by boosting 
podocyte regeneration via enhancing the capabilities of RPCs to differentiate in the presence of the 
inhibitor Glycogen synthase kinase 3, also known as BIO (glycogen synthase inhibitor 6-Bromo-
Indirubin-3´-Oxime) (27). Glycogen synthase kinase 3 treatment in-vivo using a lineage-tracing Pax2-
mT/mG reporter system significantly increased disease remission by enhancing the sensitivity of 
renal progenitors to endogenous retinoic acid. This data emphasized the possibility to 
pharmacological enhance the differentiation of RPCs by using Glycogen synthase kinase 3 (27). 
Interestingly, our previous data on CXCL12 blockade during diabetic nephropathy showed that NOX-
A12 treatment prevented the progression of glomerulosclerosis in uninephrectomized diabetic mice 
without involving glomerular leukocyte recruitment but increasing numbers of podocytes (83). Also 
Darisipudi, et al. demonstrated that CXCL12 blockade maintained podocyte numbers and renal 
Nephrin and Podocin mRNA expression during diabetic nephropathy of uninephrectomized mice. 
Consistently, CXCL12 blockade suppressed nephrin mRNA up-regulation in RPCs induced to 
differentiate toward the podocyte lineage (82). Moreover, CXCL12 blockade suppressed UACR and 
was associated with the highest levels of glomerular filtration rate (82).  However, the findings on 
diabetic nephropathy seem to be consistent, whereas the authors of the previous studies did not 
investigate whether the beneficial effects of CXCL12 blockade on podocyte numbers relates to a 
protective effect on podocyte death/detachment or from enhanced podocyte regeneration by RPCs. 
The data within this thesis now showed that extrinsic CXCL12 suppressed the proliferation of RPCs 
and their differentiation into podocytes as indicated by decreased Nephrin, Podocin, and CD2AP 
expression. In contrast, when CXCL12 was blocked using NOX-A12, RPCs were able to proliferate and 
differentiate into podocytes, highlighting an important regulatory role for CXCL12. The data herein 
provide evidence that soluble mediators released from necrotic podocytes can stimulate RPCs to 
proliferate, which was further enhanced following CXCL12 inhibition. This indicated that the 
mitogenic capacity of necrotic cell components can be dampened via intrinsic CXCL12. This was 
consistent with previous reports showing that Notch signaling is a well-characterized mitogenic 
stimulus for RPCs and podocytes (64, 149). IF staining illustrated localized expression of NICD-3 in 
podocytes and parietal epithelial cells within injured glomeruli, which markedly increased upon 
CXCL12 inhibition. This indicates that podocyte-derived CXCL12 suppresses Notch signaling, which 
further leads to the inhibition of RPCs to proliferate and to differentiate into podocytes. The healing 
phase after an acute podocyte injury was initiated can either lead to regeneration of the glomerular 
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structures and proteinuria remission or to scar formation and persistent renal dysfunction (50, 150). 
The data showed that unlike treatment with the CXCL12 inhibitor during the early onset of AN, 
CXCL12 blockade subsequently increased podocyte numbers and attenuated albuminuria, 
glomerular lesions, and renal dysfunction when AN has already been established. It is important to 
mention that the number of podocytes had further declined from week one to two in mice treated 
with the inactive CXCL12 inhibitor, whereas during the same period of time CXCL12 blockade had 
significantly increased the number of podocytes after AN has been established. This was consistent 
with a significant increase in renal Nephrin and WT-1 mRNA expression following CXCL12 blockade. 
These data suggested that CXCL12 has a dual role in acute glomerular injury and acts as a podocyte 
survival factor during the acute injury phase but promotes glomerular regeneration during the 
healing phase. The in-vitro results suggest that podocyte-derived CXCL12 enforces the quiescent 
state of podocyte progenitor cells within the PECs layer along the BC and that therapeutic CXCL12 
inhibition can enhance their differentiation into podocytes. In an in-vivo model of AN using 
Pax2.rtTA; TetO.Cre; mT/mG mice for lineage tracing of RPCs (27), CXCL12 inhibition significantly 
reduced UACR after four weeks compared to the control inhibitor, which was associated with a 
significant increase in the number of Pax2+ cells within the glomerular tuft that were also double 
positive for the podocyte marker synaptopodin. Finally, the therapeutic blockade of CXCL12 during 
the healing phase resulted in an enhancement of RPC-related podocyte regeneration and improved 
the functional outcomes of glomerular injury.  
Taken together, the data within this thesis demonstrate that the constitutive expression of 
CXCL12 by podocytes has a homeostatic effect on local stem cells conceptually similar to its role in 
the bone marrow and in other stem cell niches (Figure 49A) (151). The differential effect of CXCL12 
influences terminally differentiated podocytes and local podocyte progenitor cells during 
homeostasis, injury, and repair. Podocyte-derived CXCL12 serves as a podocyte survival factor by 
blocking the activation of the Notch signaling pathway. It is possible that CXCL12 released from 
podocytes might block the mitotic process under homeostatic conditions preventing mitotic 
catastrophe and podocyte loss during a glomerular injury (Figure 49C). Podocyte-derived CXCL12 is 
also responsible for maintaining quiescence of Pax2+ podocyte progenitor cells within the PECs layer 
along the Bowman´s capsule via suppressing Notch signaling. Although, CXCL12 is an important 
driver during homeostasis, it can limit progenitor cells to regenerate lost podocytes during a 
glomerular injury (Figure 49B). 
The data presented in this thesis also need to be interpreted under the light of our technical 
limitations. I started this research based on a previous observation within our group, that was 
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confirmed through animal models and special techniques by Romagnani and colleagues. Many 
questions have been raised but not all of them have been answered yet. I investigated the 
connection between CXCL12 and the Notch pathway using different approaches, including human 
cells and mouse models. These approaches were quite obligated considering the lack of knowledge 
and surface antibodies to identify RPCs in mice. Currently, there are no such antibodies available to 
stain for CD24 in rodent kidneys. RPCs have been characterized first in the human context due to the 
possibility using well-known surface markers like CD24 and CD133. They were used to isolate RPCs 
from fresh human kidney material and for staining them on human kidney disease biopsies (45, 135). 
The results obtained from in-vitro RPCs cell culture models are indicative. Cell culture, and in 
particular stem cell culture is a powerful method to unravel molecular mechanisms and proprieties 
of RPCs. However, one has to keep in mind that cell culture is an artificial system, where many 
variables can influence cells, e.g. medium composition, time of exposure to grow factors, percentage 
of FBS concentration, the missing microenvironment, and cell-cell contacts. These factors can 
influence the proliferation and differentiation of stem cells. So far, I have used the best known 
approaches to induce RPCs to differentiate into podocyte lineage. It is clear that in-vitro experiments 
are indispensable for the basic research, compounds first screening effects or pre-clinical drugs 
toxicity tests. However, promising drug in-vitro tests can not always predict what will happen in 
animal models or humans . 
For expanding our scientific knowledge about human diseases human clinical trials would be 
the best approach. However, this is not always possible, especially in kidney science. Even for well-
characterized and solid new experimental drugs, the way to reach the human experimentation is 
very restricted to ethical guidelines. Previously, a few cases, have been reported, where drugs were 
tested in preclinical studies that immediately got approved by the FDA without carrying out human 
trials, e.g. the immunotherapy Ab-based for B cell leukemia. Normally, the immediate solution for 
testing biological and toxic variabilities of compounds/drugs will be carried out in primates, like 
monkeys. Experiments on primate monkeys are also not available for daily basic research work due 
to ethical and moral matters, the animal number, infrastructures and the high cost involved. An 
exception are worldwide health emergencies, like the recent Ebola outbreak in West Africa and the 
HIV disease. Hence, the mouse model is predominantly the best animal model available for small 
laboratory needs. Mice have fast reproduction cycle with a lot of offspring, limited needs for space 
and relatively easy environmental life conditions. Also the mouse genetic modification opened many 
possibilities: knock-out/-in gene technology, antibiotic gene promoter inducible protein expression 
system-CRE recombinase and the cell lineage specific tracing-system, are now essential tools for 
basic researchers. However, one should always pay attention, which animal model would be 
Discussion                                                                                                                              87 
 
87 
 
appropriate in terms of efficiency, reproducibility, reliability and model contextualization. The recent 
past is full of promising models that did not fully achieve the expectations in mimicking the actual 
disease setting. In our hands, using the lineage tracing system based on the Podocin promotor (Pax2-
mT/mG system), we were able to fully characterize and trace renal stem cells in mice that are based 
on embryonic kidney observations. Currently, it is the only model available; however this might be 
replaced by a more precise technic for adult stem cell tracing in the future. We are still lacking a 
clear pattern of mouse surface markers to characterize RPCs like available for identifying human 
RPCs.  
Another experimental limitation in this thesis is the kidney disease model used. Adriamycin 
nephropathy is only one of the pathological causes inducing FSGS. Also in human FSGS does not 
represent the predominant human form of kidney disease. However, the AN mouse model is a 
reliable, fast and quite predictable model, unlike other animal models of kidney disease that are 
based on chemical induction, e.g. aristolochic acid or cisplatin tubular injury models.  Furthermore, 
within this thesis we have shown that for identifying the mechanisms connecting the Notch pathway 
and CXCL12, the timing of the treatment was essential. These differential effects of CXCL12 blockade 
could be an obstacle to perform efficient therapeutic regimes in long-term kidney diseases, e.g. 
kidney diabetes disease, kidney compliances of systemic lupus erythematosus or GBM disruption like 
the Alport syndrome .  
In conclusion, despite all these scientific limitation of this experimental work, I conclude that 
CXCL12 inhibition could be a good candidate for a novel therapeutic strategy to promote podocyte 
regeneration upon injury and to prevent progressive glomerulosclerosis, one of the most common 
causes for end-stage renal disease. 
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Figure 49. Diagram representing the renal progenitor regeneration during kidney injury. Glomerular 
compartment: The parietal epithelial cells along the Bowman´s capsule harbor RPCs. Podocytes produce 
CXCL12, which keeps the RPCs largely in an immobile and quiescent state (A). Loss of CXCL12-producing 
podocytes or therapeutic blockade of CXCL12 activates RPCs proliferation and their differentiation into 
podocytes (B). Furthermore, podocyte-derived CXCL12 also acts as a survival factor in an autocrine fashion (C). 
Discussion                                                                                                                              89 
 
89 
 
6. Conclusion 
The research presented within this thesis focused on the functional role of CXCL12 and 
glomerular regeneration during the pathogenesis of AN, and provides new insights into a potential 
pro-regenerative therapy in targeting CXCL12 to ameliorates CKD. 
The findings of the current study have multiple implications that are listed as followed  
 Podocyte secrete CXCL12 
 CXCL12 blockade can attenuate progressive glomerulosclerosis 
 In-vitro CXCL12 protected human podocytes from toxic injury  
 In-vivo early blockade of intrinsic CXCL12 aggravated proteinuria 
 Continued blockade of intrinsic CXCL12 during the course of ADR nephropathy significantly 
attenuated podocyte loss, proteinuria, and glomerulosclerosis. 
 CXCL12 suppressed progenitor growth  
 CXCL12 blockade significantly increased podocytes via Pax2+  mouse podocyte progenitor-
mediated podocyte regeneration 
Taken together, the findings highlight the importance of podocyte-derived CXCL12 as a crucial 
mediator of RPC regeneration during FSGS. 
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7. Future Directions 
 Podocyte-derived CXCL12 has been shown to serve as a podocyte survival factor during 
podocyte injury and can promote podocyte progenitor quiescence. Future investigations are needed 
to unravel the molecular mechanisms associated with podocyte mitotic catastrophe. Miotic 
catastrophe is an ongoing process during AN, which has been proven by the group of Romagnani. 
Within this thesis, CXCL12 can act as a survival factor for podocytes by preventing Notch-mediated 
mitotic catastrophe of podocytes highlighting a link between CXCL12 and the Notch pathway during 
the process of mitotic catastrophe.  
One way to investigate this is to perform an experimental model of AN based on a Podocin-lineage-
tracing system. Similar to the previously used Pax2 mouse model, the induction of a specific 
podocyte tomato red/green report system would be very useful. Following induction of AN, mice will 
be treated with the CXCL12 inhibitor NOX-A12 and control revNOX-A12 for two weeks. To test the 
consequent impact of Notch signaling on CM and regeneration of podocytes, mice will be treated 
with the Notch inhibitor DAPT at the same time like the NOX-A12 during AN (Figure 46). The final 
readout in this model will be to quantify the remaining number of green-EGFP-podocin podocytes 
after the induction of CM compared to the control. This will provide further insight into the 
mechanisms by which CXCL12 regulates podocyte mitotic catastrophe and regeneration of 
podocytes.  
 
Figure 50. Adriamycin nephropathy model in Balb/c using CXCL12 and Notch inhibitors 
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9. Abbreviations 
AN  ADR-induced nephropathy 
ATN Acute Tubular Necrosis 
ATRA All-Trans Retinoic Acid 
AKI Acute Kidney Injury 
UACR Urinary Albumin to Creatinine Ratio 
ADR Adriamycin 
BUN Blood Urea Nitrogen 
CD24 Cluster of Differentiation-24 
CD133 Prominin-1 
CKD Chronic Kidney Disease 
CXCL12/SDF-1 Stromal Derived Factor- 1  
CD2AP CD2-Associated Protein 
CXCR Chemokine C-X-C motif Receptor 
DAPT N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
Dll-1 Delta-like protein 1 
DMEM-F12 Dulbecco Eagle Modified Medium Ham F-12 
DT Diphtheria Toxin 
EBM Endothelial Cell Basal Medium 
ERSD End Renal Stage Disease 
EGM-MV Endothelial Cell Growth Medium 
FSGS Focal Segmental Glomerulosclerosis 
GBM Glomerular Basement Membrane   
GN Glomerulonephritis 
BIO Glycogen synthase inhibitor 6-bromo-indirubin-3´-oxime 
Hey-1 Hairy/enhancer-of-split related with YRPW motif protein 1 
Hes-1 Hairy and enhancer of split-1 
HEK Human embryonic Kidney cells 
IF Immunofluorescent staining 
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IHC  Immunohistochemistry staining 
Jag-1 Jagged-1 
Jag-2 Jagged-2 
KDIGO Kidney Disease Improving Global Outcomes 
MPGN Membrano-proliferative glomerulonephritis  
NPHS1 Nephrin 
NPHS2 Podocin 
Notch-1 Notch homolog 1, translocation-associated 
Notch-2 Notch homolog 2, translocation-associated 
Notch-3 Notch homolog 3, translocation-associated 
NICD-1 Notch Intracellular Domain-1 
NICD-3 Notch Intracellular Domain-3 
NS Podocyte’s derived necrotic Supernatant 
PAS Periodic acid–Schiff staining 
PECs Parietal epithelial cells 
RA Retinoic Acid 
RPCs Human renal progenitor cells 
TLRs Toll-like Receptors 
TECs Tubular epithelial cells 
SCID Severe Combined Immunodeficiency 
FSGS Focal segmental glomerulosclerosis 
VEGF Vascular Endothelial Growth Factor 
WT-1 Wilm´s tumor 1 
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10.  Appendix 
Composition of buffers used 
FACS Buffer: BSA 3%, NaN3 0.05% and PBS1x (see below)-1 
IF Buffers: PBS1x, BSA3%,PBS1x, 0.5% Saponin 
RIPA Buffer: 
50 mM Tris-HCl (pH 8);150 mM NaCl, 1% NP-40; 0,05%sodium 
deoxycholate, 0.1% SDS  
For 1000 ml Tris-HCL   6.057 g, NaCl 8.772 g, NP-40 10mL, Sodium deoxycholate 0.5mL,  
SDS 1mL 
EDTA 2mM: EDTA 7.44 mg in 10 ml HBSS (without Ca, Mg) To be preheated in 37 °C 
water bath before use 
PBS: 2.74 M NaCl, 54mM KCl, 30mM KH2PO4, 130mM Na2HPO4, in ddH20, adjust 
to pH 7.5 with HCl 
Gel Running Buffer 
10x: 
Tris-NaCl 30g, Glycine 144g, SDS 5g make up volume 1000mL with pH 8.3 
Transfer Buffer 1x: Tris-Nacl 1.5g, Glycine 7.2 make up to 500mL 
TBS 10x: Tris 24.23g, NaCl 80.06g, HCl circa 17.5mL and make up volume 1000mL 
(pH7.6) 
TBS-T 1x: TBS (1x) 1000mL and Tween 20 1mL 
Sample Buffer: Millipore water 3.8mL , 0.5 M Tris-NaCl pH6.8 1mL, Glycerol 0.8mL, 10%SDS 
1.6mL, 2-mercaptoethanol 0.4mL and 1% Bromophenol 0.4mL 
Separating Buffer: Tris (1.5mM), SDS 400mg muke up volume to 100mL (pH8.8) 
Stacking Buffer: Tris (0.5M), SDS 400mg make up volume to 100mL (pH6.8) 
Staining Solution: Methanol 500mL, Acetic acid 100mL, Water 400mL, Coomasie Brilliant Blue 
R 2.5g (0.25%) 
Destaining solution: Methanol 150mL, Acetic Acid, 100mL, Water 750mL 
 
 
 
 
 
 
 
 
 
 
 
 
103 
 
  
Florence, 1 November  2015 
  
 
 
 
 
  
Duccio Lombardi and Laura Lasagni, we declared that Simone Romoli, from the University of Munich-
LMU, got the permission to include inside his Ph.D thesis, our figures from the article “Transgenic 
Strategies to Study Podocyte Loss and Regeneration”.  Accordantly with the international copyright 
rules of Creative Commons Attribution License, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
 
 
 
 
 
 Laura Lasagni 
 
 
 
 
Duccio Lombardi 
 
 
 
 
 
 
 
 
104 
 
Acknowledgement 
It’s time to say thank you for these wonderful and full four years of life in Bavaria. 
There are not enough words to express my gratitude to my mother, my sister, my father and to all my 
grandmothers, for their constant love and encouragement through my abroad adventure. Grazie di cuore. 
I would like to thanks and to express my gratitude to my mentor and supervisor Prof. Dr. Hans-Joachim Anders. 
He provided me guidance and advice during my research work. I appreciated his trust in my scientific skills and 
support which contribute to my progress as a scientist.  
Many thanks to all my “German” colleagues and friends, from Munich: Julian, Alexander, Jyaysi, Mohsen, Marc, 
Dana, Khader, Kirstin, Henny, Maciej, Mi, Onkar, Tomo, Daigo, Mary, Jenny, Bea, Anais, Andrei, Melissa, Martin, 
Jhon, Jhonny, Nico, Anja and all medical students for all your help and for the delightful time we had together.   
Many thanks are necessary for Dr. Bruno Luckow, Dr. Volker Vielhauer and Dr. Peter Nelson and their 
respective teams for their support and suggestions during my research work throughout my stay in the 
Nephrology Center.  
Special and super thanks to Katharina Witte. I will miss you “mama”. 
Many thanks to my Garching Italian friends: Nicola, “Parente” and Michele.  Grazie di tutto! 
It is my pleasure to thank Prof. Dr. Stefan Endres, Leader of GRAKO1202, LMU, for allowing me to become a 
member of graduate students network during my Ph.D. and for the incredible experience of the Immunofest. 
I would like to acknowledge Prof. Paola Romagnani (University of Florence, Italy) for giving me the opportunity 
to perform part of my work on their laboratory and providing me outstanding experimental supports for my 
research work. 
Many thanks to all the lab colleagues and friends, from Florence; Anna, Elena, Laura, Marialucia, Francesca. 
Benedetta, Duccio, Sara, for all your help and for the delightful time we had together.   
I would like to express my gratitude to Ewa, Dan, and Jana for providing skillful technical assistance to carry out 
the research work successfully. 
Especially to Shrikant and Santhosh, thank you, you have helped me and have been my friend since the first day 
of my adventure in Munich. Thank you for sharing your knowledge and for listening me every time, and for all 
your precious help and support as colleague, but moreover as incredible friends.  India it will be always in my 
heart. 
Special gratitude to all my friends all over the word, who always gave me support and encouragement: Arianna, 
Francesco, Marta e Alessandro. 
Grazie a tutti i miei amici di Firenze per tutto il supporto in questi anni. 
A billion of thanks goes to Adriana, for all. 
Steffy, I want say, thank you from my heart, to be such an incredible person, impressive scientist and 
outstanding friend, without you, this work and my future would not be the same. Guida sempre veloce! 
I am grateful to everybody who has been part of my life but I failed to mention their names. Thank you all 
Folks!  
 
 
